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ABSTRACT
GWAS have identified several chromosomal loci associated with ovarian cancer
risk. However, the mechanism underlying these associations remains elusive. We
identify candidate functional Single Nucleotide Polymorphisms (SNPs) at the 9p22.2
ovarian cancer susceptibility locus, several of which map to transcriptional regulatory
elements active in ovarian cells identified by FAIRE-seq (Formaldehyde assisted
isolation of regulatory elements followed by sequencing) and ChIP-seq (Chromatin
Immunoprecipitation followed by sequencing) in relevant cell types. Reporter and
electrophoretic mobility shift assays (EMSA) determined the extent to which candidate
SNPs had allele specific effects. Chromosome conformation capture (3C) reveals a
physical association between Basonuclin 2 (BNC2) and SNPs with functional properties.
This establishes BNC2 as a major target of four candidate functional SNPs in at least
two distinct elements.
BNC2 codes for a putative transcription regulator containing three pairs of zinc
finger (ZF) domains. Furthermore, bnc2 mutation in zebrafish leads to developmental
defects including dysmorphic ovaries and sterility, clearly implicating this protein in
cellular processes associated with ovarian development. We show that BNC2 is a
transcriptional regulator with a specific DNA recognition sequence of targets enriched in
genes involved in cell communication through DNA binding assays, ChIP-seq, and
expression analysis.

vii

This study reveals a comprehensive regulatory landscape at the 9p22.2 locus
and indicates that a likely mechanism of susceptibility to ovarian cancer may include
multiple allele-specific changes in DNA regulatory elements some of which alter BNC2
expression. This study begins to identify the underlying mechanisms of the 9p22.2 locus
association with ovarian cancer and aims to provide data to support advances in care
based on one’s genetic composition.

viii

CHAPTER ONE:
BACKGROUND

Ovarian Cancer
Ovarian cancer is one of the leading causes of cancer deaths among women in
the United States. It is a poorly understood disease often diagnosed at late stages and
consequently with low five year survival rates (Vaughan et al., 2011). In fact, the five
year survival rate has plateaued at 40% since the introduction of platinum based
therapies in the late 1970s (Vaughan et al., 2011). One reason for the low survival and
lack of improvements in therapy is that ovarian cancer has been treated as one disease
when in actuality it is made up of different subtypes with diverse cellular origins and
molecular pathways altered (Berns and Bowtell, 2012; TCGA, 2011). Additionally the
pathogenesis of ovarian cancer is unclear. Identifying risk factors and those with a
genetic predisposition would aid in identifying the disease and therefore lead to
increased survival.

Ovarian Cancer Subtypes
Four different subtypes, mucinous, clear cell, endometrioid, and serous pertain to
ovarian cancer. Evidence suggests that the mucinous subtype derives from metastases
to the ovary from gastrointestinal tumors (Kelemen and Kobel, 2011; Lee and Young,
2003). Clear cell and endometrioid subtypes originate in the endometrium and are often
1

linked with endometriosis (Nezhat et al., 2008). The most common and most lethal
subtype, high grade serous ovarian cancer, was initially thought to originate in the
ovarian surface epithelium (OSE). The cancer is often found at late stages and fills the
peritoneal cavity making it difficult to discern the cell of origin. Yet, significant evidence
also supports that the secretory cells in the fimbria of the fallopian tube contribute to the
origin of high grade serous ovarian cancer (Carlson et al., 2008; Lee et al., 2007; Piek
et al., 2001).
High grade serous ovarian cancer in itself seems to be very heterogeneous in
that many patients experience different outcomes (Tan et al., 2013). Indeed, high grade
serous ovarian cancer is made up of different molecular subtypes defined by expression
analysis and clustering of ovarian tumor samples (Leong et al., 2015; Tan et al., 2013;
TCGA, 2011; Tothill et al., 2008). These molecular subtypes include mesenchymal,
immuno-reactive, differentiated, and proliferative (Leong et al., 2015; TCGA, 2011). The
mesenchymal subtype displays severe myofibroblast infiltration and has an epithelial to
mesenchymal gene expression signature (Leong et al., 2015; Tan et al., 2013; TCGA,
2011; Tothill et al., 2008). The WNT/beta-Catenin and Extra Cellular Matrix Pathways
are altered and HOX genes and FAP, a stromal component, are over-expressed
(TCGA, 2011; Tothill et al., 2008). This subtype also has poor prognosis (Leong et al.,
2015; Tan et al., 2013; Tothill et al., 2008). The immune-reactive subtype displays TCell infiltration and expresses T-Cell chemokine ligands (Leong et al., 2015; TCGA,
2011; Tothill et al., 2008). This subtype has an intermediate prognosis (Leong et al.,
2015; Tothill et al., 2008). The differentiated subtype expresses ovarian tumor markers
MUC1 and MUC16 as well as the fallopian tube marker SLP1 (Leong et al., 2015;
2

TCGA, 2011). This subtype also has an intermediate response (Leong et al., 2015). The
last subtype, proliferative, expresses stem cell factors including transcription factors
(TFs) HMGA2 and SOX11 (Leong et al., 2015; TCGA, 2011) This subtype also has low
expression of ovarian tumor markers MUC1 and MUC16 and high expression of
proliferation markers MCM2 and PCNA (TCGA, 2011). This subtype has a poor
prognosis yet seems to be sensitive and respond well to vinca alkaloids (Leong et al.,
2015; Tan et al., 2013).

Risk Factors and Pathogenesis
Since high grade serous epithelial ovarian cancer (EOC) is diagnosed at an
advanced stage in 70% of patients and these patients have a worse outcome than
those with early stage disease (Vaughan et al., 2011), identifying those at risk may lead
to early detection and therefore decreased mortality. One known risk factor that
significantly influences ovarian cancer is low parity (Braem et al., 2010; Hinkula et al.,
2006; Salehi et al., 2008; Sueblinvong and Carney, 2009). In fact, women who have
children have a decreased risk of 71% and the risk further decreases by 10% with each
live birth (Braem et al., 2010). Oral contraceptive use and shorter menstrual lifespan
also decrease risk of ovarian cancer (Bosetti et al., 2002; Braem et al., 2010; Hankinson
et al., 1992; Modugno et al., 2004; Salehi et al., 2008; Sueblinvong and Carney, 2009).
Pregnancy, oral contraceptives, and shorter menstrual lifespan all decrease the number
of ovulations in a lifetime.
There is no clear evidence for the pathogenesis of ovarian cancer but several
hypotheses exist based on the number of ovulations/menstrual cycles in a lifetime. The
3

first hypothesis states that incessant ovulation leads to damage of the ovarian surface
epithelium which in turn leads to malignant cells (Fathalla, 1971; Riman et al., 1998).
Another hypothesis suggests that granulosa and theca cells fail to undergo apoptosis
after ovulation (Cramer et al., 2002; Hanna and Adams, 2006). Another hypothesis
suggests that high levels of gonadotropins increase stimulation of estrogen, which
entraps ovarian epithelial cells in inclusion cysts which leads to malignant cells (Hanna
and Adams, 2006; Zheng et al., 2007). Higher androgen levels lead to cancer while
higher levels of progestin prevent cancer (Bu et al., 1997; Hanna and Adams, 2006;
Risch, 1998; Zheng et al., 2007). Pregnancy and oral contraceptives decreases
gonadotropin and androgen levels while increasing levels of progestin, therefore
preventing cancer (Sueblinvong and Carney, 2009). Finally, inflammation potentially
plays a major role in ovarian cancer development (Hanna and Adams, 2006; Ness et
al., 2000; Salvador et al., 2009). During menstruation, retrograde flow brings
inflammatory mediators (bacteria, chemicals, etc.) to the fallopian tube and therefore
inflammation within the fallopian tube (Maisey et al., 2003; McGee et al., 1999; Salvador
et al., 2009; Strandell et al., 2004). Inflammation within the fallopian tube causes cells to
rapidly divide and increase the potential for DNA replication errors and thus
development of a malignant cell (Ames et al., 1995; Dreher and Junod, 1996; Nash et
al., 1999; Pagano et al., 2004; Salvador et al., 2009). Oral contraceptives and
pregnancy decrease and eliminate menstruation respectively and therefore decrease
retrograde flow (Brosens and Vasquez, 1976; Group, 2005; Lindblom et al., 1980;
Salvador et al., 2009). Also oral contraceptives and pregnancy increase the cervical
mucus thickness which protects the uterus from inflammatory mediators (Pal and
4

Bhattacharyya, 1989; Salvador et al., 2009). This theory has the most effect on the
fallopian tube suggesting that inflammation may be the most likely pathogen for ovarian
cancer (Salvador et al., 2009).

Genetic Predisposition to Ovarian Cancer
Family history is also a risk factor for ovarian cancer. Ovarian cancer is a
seemingly inherited disease in that women with a first degree affected relative have an
increased risk of developing ovarian cancer compared to the general population
(Pharoah and Ponder, 2002; Stratton et al., 1998). Risk further increases in families with
mutations in BRCA1 and BRCA2 by 45% and 25% respectively (Antoniou et al., 2002;
Ford et al., 1998; Minion et al., 2015; Pharoah and Ponder, 2002). Germline mutations
in mismatch repair genes (MMR) genes such as MLH1, MSH2, MSH6, PMS2, and
EPCAM, also known as Lynch Syndrome causes 2% of ovarian cancer cases (Lu and
Daniels, 2013; Malander et al., 2006; Minion et al., 2015; Pennington and Swisher,
2012; Pennington et al., 2014; Walsh et al., 2011). Lynch syndrome was first identified
in families with colorectal cancer and the ovarian cancer patients with mutations in MMR
genes have a family history of colorectal cancer (Malander et al., 2006; Meyer et al.,
2009). Mutations in BRCA1 and BRCA2 lead to high grade serous ovarian cancer while
mutations in MMR genes more likely lead to endometrioid and mucinous ovarian cancer
(Berns and Bowtell, 2012; Chiaravalli et al., 2001; Fujita et al., 1995; King et al., 1995;
Turner et al., 2004).
Highly penetrant pathogenic alleles of known susceptibility genes such as
BRCA1/BRCA2 and MMR genes only account for 11% and 2% of high grade serous
5

EOC and endometrioid/mucinous in the general population, and less than half of all
familial ovarian cancer cases (Malander et al., 2006; Pharoah and Ponder, 2002;
Ramus et al., 2007). These genes have been identified by performing family-based
linkage studies (Miki et al., 1994; Wooster et al., 1995). Germline mutations in highly

Figure 1. Effect size versus allele frequency of ovarian cancer susceptibility
genes. This figure displays all known ovarian cancer susceptibility genes graphed by
their approximate effect size and allele frequency in the population. This mainly portrays
that the genetic contribution to risk includes high effect size/penetrance genes,
intermediate effect size/penetrance genes and low effect size/penetrance loci.

6

penetrant cancer susceptibility genes TP53 and PTEN have also been found in ovarian
cancer cases (Minion et al., 2015; Pennington and Swisher, 2012; Pennington et al.,
2014). However, exhaustive family-based linkage studies have not found novel highly
penetrant genes (Pharoah et al., 2004). Additional studies have found variants with
intermediate penetrance affecting ovarian cancer risk including several genes in the
Fanconia Amenia pathway; BARD1, BRIP1, MRE11A, NBN, PALB2, RAD50, RAD51C,
RAD51D, CHEK2, as well as CHEK1 and ATM (Baysal et al., 2004; Casadei et al.,
2011; Castera et al., 2014; Coulet et al., 2013; Kanchi et al., 2014; Kuusisto et al., 2011;
Meindl et al., 2010; Pennington and Swisher, 2012; Pennington et al., 2014; Rafnar et
al., 2011; Thorstenson et al., 2003; Walsh et al., 2011) Mutations in genes like BRCA1
and BRCA2, with a high effect size or high penetrance, are very rare in the population
(Figure 1) (Manolio et al., 2009). Mutations in intermediate penetrance genes are
usually rare to low frequency variants (Figure 1) (Manolio et al., 2009). The remaining
genetic contribution to risk in ovarian cancer may be explained by common variants with
a low effect size (Figure 1) (Manolio et al., 2009).

Genome Wide Association Studies
Genome wide association studies (GWAS) identify the common variants
associated with complex, common disease, such as ovarian cancer (Cardon and Bell,
2001; Pharoah et al., 2004; Risch and Merikangas, 1996; Risch, 2000). GWAS identify
predisposition loci by genotyping thousands of SNPs in thousands of cases and
thousands of controls to find the common low penetrant alleles that significantly occur
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more frequently in the cases than in the controls (Cardon and Bell, 2001; Carlson et al.,
2004; Pharoah et al., 2004; Risch and Merikangas, 1996; Risch, 2000).

Linkage Analysis versus GWAS
Linkage analysis identifies genetic variants associated with diseases that follow
the mendelian pattern of inheritance, meaning one gene affects one trait with two (or

Figure 2. Penetrance of inherited variants. Carriers of variants (individuals outlined in
red) can make up a small proportion of the population or larger proportion of the
population depending on the type of variant and how it influences disease and fitness.
Rare variants tend to have high penetrance with the majority of carriers developing the
disease (red individuals) while common variants tend to have low penetrance.
8

very few) phenotypes (Jimenez-Sanchez et al., 2001). The disease associated variant is
rare in the population and highly penetrant or in other words, carriers of the variant have
a high likelihood of developing the disease (Pritchard, 2001; Reich and Lander, 2001)
(Figure 2). Linkage analysis utilizes pedigrees of affected families to identify genetic
markers with a known location in the genome that inherit with the disease gene during
meiosis. Since regions of the genome that are in close proximity are less likely to
recombine onto separate chromosomes, this allows for the identification of a location for
the disease gene. Sequencing and identification of variants in the human genome
attributed to the success of linkage analysis (International HapMap, 2005; Lander et al.,
2001; Venter et al., 2001). Variations identified via linkage analysis often change protein
coding sequences and therefore affect the function of the gene.
GWAS analysis identifies genetic variants associated with complex, common
diseases or diseases that follow a non-Mendelian pattern of inheritance (Cardon and
Bell, 2001; Manolio, 2010; Pharoah et al., 2004). These traits are polygenic, meaning
multiple genes affect one trait with a wide range of phenotypes. The disease associated
variants are common in the population, yet, a small proportion of carriers of a single
disease associated variant will develop the disease since these variants, alone, have a
small effect size (Cardon and Bell, 2001; Risch and Merikangas, 1996) (Figure 1 and 2).
In order to obtain the statistical power that a variant associates more frequently with the
disease than controls, GWAS genotype thousands of SNPs (common SNPs with a
minor allele (MAF) > 0.05) in thousands of cases and thousands of controls (Cardon
and Bell, 2001; Carlson et al., 2004; Colhoun et al., 2003; Dahlman et al., 2002; Hunter
and Kraft, 2007; Manolio, 2010; Pharoah et al., 2004; Risch and Merikangas, 1996).
9

Statistical power also depends on the effect size (Stranger et al., 2011). By increasing
the number of cases and controls, a GWAS will identify variants the have a smaller
effect size (Manolio, 2010). In GWAS, the causal SNPs often change the sequence of
non-coding DNA (Hardy and Singleton, 2009; Manolio, 2010). In general changing the
sequence of non-coding DNA, has a less dramatic effect than changing an amino acid
sequence of a protein, thus differences in effect size.

Principles of GWAS
The variant identified as associated with the disease in GWAS is called the
tagging SNP. The tagging SNP represents all linked SNPs or in other words all SNPs
that frequently inherit with that SNP after recombination during meiosis (Carlson et al.,
2004; Gabriel et al., 2002). Regions of the genome being inherited together rather than
independently is a phenomenon called linkage disequilibrium (LD). The tagging SNP
tells us that any variation within a LD structure could be considered the causal variant
(Carlson et al., 2004; Gabriel et al., 2002; Pharoah et al., 2004) (Figure 3). This allows
for the genotyping of a subset of SNPs rather than all SNPs within the genome (Carlson
et al., 2004; Pharoah et al., 2004). The HapMap project determined patterns of LD in
the human genome among different ethnicities to allow for the selection of SNPs in
GWAS (International HapMap, 2005). When selecting the tagging SNPs, it is important
to keep in mind that patterns of LD are different among ethnicities (Carlson et al., 2004).
R2 and d-prime are pairwise measurement of LD between SNPs. If r2 = 1 and dprime = 1 then two of four possible haplotypes are present (Pharoah et al., 2004). The
first haplotype would be the major allele for both SNPs and the second haplotype would
10

Figure 3. Tagging SNP represents many candidate causal SNPs in LD. SNPs that
frequently inherit together during meiosis are in LD and are represented by LD
structures. The increase in red intensity in the LD plot shown here, indicate SNPs in
increasing LD measured by d-prime. One can visualize LD structure by breaks in red
color. A tagging SNP (in yellow) would represent all SNPs within the LD structure (in
blue) as potential candidate causal SNPs. SNPs outside that LD structure (in black) are
not potentially causal.

be the minor allele for both SNPs. Neither site has experienced mutation or
recombination between the sites (Carlson et al., 2004). If d-prime and r2 < 1 then more
than two haplotypes are present (Pharoah et al., 2004). Allele frequency also influences
r2 since a low frequency allele is less likely to occur in a haplotype (Pharoah et al.,
2004). r2 = 1 only when the two variants have the same MAF (Carlson et al., 2004).
To manage the high cost of such studies, the analysis is often done in tiers
(Manolio, 2010; Pharoah et al., 2004). The first tier is testing all possible tagging SNPs
throughout the genome in a smaller set of cases and controls. Those SNPs that surface
as significant at an arbitrary threshold are genotyped again in a larger set of cases and
11

controls. The final tier genotypes the SNPs that remained significant at a higher
arbitrary threshold in tier 2 in an even larger set of cases and controls with the final
SNPs reaching genome wide significance (Manolio, 2010; Pharoah et al., 2004). This
process eliminates false positives and allows false negatives to surface (Manolio, 2010).
Additionally, meta-analyses of independent GWAS increase sample size and statistical
power (Stranger et al., 2011).
SNPs with a p-value < 5 x 10-8 are considered genome-wide significant. This is a
Bonferroni correction based on multiple testing hypothesis since a GWAS genotypes
approximately 1 million SNPs which, based on LD, seems to provide complete coverage
of the genome (Hirschhorn and Daly, 2005; Stranger et al., 2011).

Caveats of GWAS
After hundreds of GWAS, many diseases still have missing heritability due to the
lack of statistical power of a causal allele. The causal allele may not have been
thoroughly represented by a tagging SNP due to correlation and/or differences in allele
frequency (Stranger et al., 2011). One possibility for missing heritability is that there are
rare variants with modest effect which would not be detected by GWAS (Manolio et al.,
2009). The 1000 Genomes Project has sequenced 2,000 individuals to begin identifying
low frequency variants (MAF = 0.001 – 0.005) but detecting association would still
require sequencing of thousands of cases and controls (Genomes Project et al., 2010;
Manolio et al., 2009). GWAS also lacks the ability to detect structural variants or copy
number variation (Manolio et al., 2009). It is still unclear whether multiple variants
associated with the disease are additive or non-additive in measuring susceptibility.
12

Additive would mean that each variant has an effect size and carriers of more than one
disease variant would have a combined effect size of those variants (Hirschhorn and
Daly, 2005; Manolio et al., 2009; Stranger et al., 2011). If some variants are nonadditive, determining risk becomes more complex. Non-additive genetic variance
includes interactions between loci such as dominance and epistasis as well as
interaction between loci and environment (Hirschhorn and Daly, 2005; Manolio et al.,
2009; Stranger et al., 2011). If the latter is the case, then fewer variants are required to
explain the heritability (Hirschhorn and Daly, 2005). If multiple alleles at a disease
susceptibility locus confer susceptibility, the power of LD mapping approaches decrease
because each variation will arise on a different haplotype background (Pharoah et al.,
2004). Since for many diseases there is still a gap in the heritability, risk assessment for
individuals will not be of clinically useful predictive value (Jakobsdottir et al., 2009;
Manolio, 2010; Wray et al., 2008).

Ovarian Cancer GWAS
Genome-wide association studies (GWAS) have identified a total of 20 loci
associated with risk of ovarian cancer (Figure 1 and 4) (Bojesen et al., 2013; Bolton et
al., 2010; Chen et al., 2014; Kuchenbaecker et al., 2015; Permuth-Wey et al., 2013;
Pharoah et al., 2013; Shen et al., 2013; Song et al., 2009). The first ovarian cancer
GWAS was done in three tiers and identified the locus 9p22 as associated with ovarian
cancer (Song et al., 2009). They then re-analyzed the data to see if the associated SNP
was more associated with a specific subtype of ovarian cancer (Song et al., 2009). It
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was only significantly associated with the serous ovarian cancer subtype (Song et al.,
2009).
Another GWAS that looked at survival in ovarian cancer identified a SNP on
19p13 (Bolton et al., 2010). Yet, this SNP did not replicate in the final study (Bolton et
al., 2010). It did replicate as associated with serous ovarian cancer (Bolton et al., 2010).

Figure 4. EOC Susceptibility Loci. Each EOC susceptibility loci identified in ovarian
cancer GWAS has been plotted here based on their odds ratio (frequency in
cases/frequency in controls) and EOC GWAS significance. These loci are associated
with serous EOC, BRCA1/BRCA2 mutation carriers and all histoligies, BRCA1/BRCA2
mutation carriers and serous EOC, clear cell EOC, and BRCA1 mutation carriers.
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After these initial ovarian cancer GWAS, investigators realized that stratifying by
subtype may allow for the discovery of more associated SNPs since phenotypic
heterogeneity can reduce power (Goode et al., 2010; Ioannidis et al., 2009). Many of
these loci also displayed associations with carriers of BRCA1 and BRCA2
(Kuchenbaecker et al., 2015; Ramus et al., 2012; Ramus et al., 2011). One locus was
identified that associated with BRCA1 mutation carriers only (Couch et al., 2013). This
suggests that low risk common variants interact multiplicatively with high risk rare
variants in susceptibility to EOC (Kuchenbaecker et al., 2015). This then led to a GWAS
meta-analyses of data from ovarian cancer cases unselected for family history, ovarian
cancer cases with BRCA1 mutations, and ovarian cancer cases with BRCA2 mutations,
which retrieved additional EOC susceptibility loci (Kuchenbaecker et al., 2015).
The EOC susceptibility loci identified so far explain 3.9% of the excess familial
risk of EOC in the general population, 5.2% in BRCA1 carriers, and 9.3% in BRCA2
mutation carriers (Kuchenbaecker et al., 2015). The identification of these loci may be
useful for risk assessment in individuals who carry mutations in BRCA1 and BRCA2, yet
their contribution to risk in the general population is still too low to be useful. Yet, these
studies provide a starting point for the discovery of pathways and mechanisms
operating in ovarian oncogenesis. Delineation of these pathways may reveal novel
therapeutic strategies, much in the same way the identification of BRCA1 and BRCA2
and their role in homology-directed recombination led to the use of synthetic lethality
with PARP1 inhibition in breast and ovarian cancer (Fong et al., 2009). However, the
mechanistic underpinnings of these susceptibility loci remain largely unknown.
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Functional Analysis of Susceptibility Loci
Several studies have performed functional analysis of susceptibility loci with
different degrees of depth of investigation on how these susceptibility loci influence
disease predisposition. From the experience of previous functional analysis of GWAS
loci, described here is a thorough and potential flow of questions to analyze a locus
(Figure 5). To begin functional analyses of the mechanisms of susceptibility of disease
loci, all correlated SNPs must be identified since tagging SNPs are not necessarily the
functional SNP, rather they are a surrogate marker for the locus (Carlson et al., 2004;
Gabriel et al., 2002). Correlated SNPs can be retrieved using an arbitrary threshold of
LD by obtaining data from the 1000 Genomes Project and performing haplotype
analysis with the Haploview program (Barrett et al., 2005). Interestingly the majority of
associated and correlated SNPs reside in non-coding regions of the genome (Maurano
et al., 2012). Since these SNPs do not disrupt the amino acid sequence of proteins in
the cell to disrupt cellular processes, it is hypothesized that associated SNPs exert their
effects through changing the transcription activity of enhancers and promoters and
therefore affecting the transcription rates of target genes (Freedman et al., 2011).
Fortunately, The Encyclopedia of DNA Elements (ENCODE) discovered that
80% of the genome has a biological function in at least one cell type (Dunham et al.,
2012). Many of these functions are cell type specific indicating the importance of
choosing the cell type for functional analyses (Heintzman et al., 2009).
After identifying which SNPs localize within a regulatory element, the next step is
to identify which SNPs have allele specific activity. This is then followed by identifying
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Figure 5. Flow chart for the functional analysis of cancer susceptibility loci.

the downstream target gene whose transcription is affected by allele changes at the
causal SNP (Figure 5). Genes within an arbitrary distance of the causal SNP can
constitute the universe of candidate target genes for functional analysis. Within 1
megabase (Mb) of the causal SNP is within reason since very few enhancers loop to
genes at a farther distance although, it is possible (Jin et al., 2013).
The next step would be to examine ways to link SNPs and genes (Figure 5). The
final step would be to explore how these changes in alleles and expression of target
genes result in disease, or in this discussion cancer. This last and final step would be an
ongoing exploration and depending on the gene and pathways disrupted, would require
different scientific techniques to analyze (Figure 5). Since risk variants identified by
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GWAS, individually, contribute a small percentage of risk, presumably, these variants
will have small effects on biological functions. Ultimately, functional analyses of GWAS
loci uncover the mechanisms by which genetic variation influences risk.

Transcriptional Regulation
Since it is hypothesized that allele changes of GWAS SNPs most likely effect the
transcription function of enhancers and promoters, a clear understanding of and
development of functional assays is needed to identify the causal SNP. Regulation of
transcription determines cell identity in development and maintains homeostasis of the
cell. Aberrant transcription can lead to severe changes in the biological processes of a
particular cell. Transcription is quite complex in that it is under combinatorial control
(Britten and Davidson, 1969). Different genes are regulated by different combinations of
TFs in a cell type specific manner (Britten and Davidson, 1969). Therefore, functional
analysis of GWAS hits requires identification of a transcription regulatory network at a
locus and where the glitch in the network, caused by the associated SNP, resides.

Basics of Transcriptional Regulation
There are three main DNA regulatory elements in transcription. The core
promoter resides immediately upstream and adjacent to the transcription start site
(TSS). General TFs bind to the core promoter. The general TFs make up a group of
proteins that have or support the catalytic processes necessary for transcription
elongation. The next regulatory element is the regulatory promoter and it lies
immediately upstream of the core promoter. It recruits co-activating/repressing TFs that
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help recruit and activate or block and repress general TFs to the core promoter. The
final regulatory element is the enhancer which lays several kilobases (kb) upstream or
downstream of the core promoter. It loops to the core and regulatory promoter to aid in
recruiting co-activating/repressing TFs. Enhancers also seem to be cell type specific
and make up the majority of regulatory elements in the genome (Thurman et al., 2012).
The core promoter is generally inactive in vivo without the regulatory promoter and/or
enhancer. Since enhancers make up the majority of regulatory elements in the genome
and have a greater influence on transcription activity, causal SNPs have a higher
probability of influencing the function of an enhancer.
For DNA to fit and function in the nucleus, it has a specific structure and
conformation specific to particular cell types. DNA is packaged into nucleosomes by
wrapping around histone octamers which in turn package into chromatin. These
histones also regulate which regions of DNA are accessible to TFs since chromatin
needs to be de-condensed for activation at promoters and enhancers by specific TFs
(Cairns, 2009). Chromatin loops bring together enhancers and promoters and organize
the chromatin into areas of euchromatin (active) and heterochromatin (in-active).
The transcription cycle can be described in several steps (Reviewed in (Fuda et
al., 2009). The first step involves clearing of nucleosomes from enhancers and
promoters by specific TFs with the ability to bind to nucleosome bound DNA or at linker
DNA between nucleosomes (Hebbar and Archer, 2003). Additional nucleosome
remodeling TFs are recruited to further make DNA accessible. The second step
involves the binding of co-activators which in turn recruit general TFs and RNA
polymerase II to the core promoter. In the third step, DNA begins to unwind and RNA
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polymerase II initiates transcription. In the fourth step, co-activators phosphorylate RNA
polymerase II which then escapes the core promoter and pauses. The fifth step requires
further phosphorylation of RNA polymerase II to elongate and continue transcription of
the gene. In the sixth step, RNA polymerase II elongates through the whole entire gene.
In step seven, transcription terminates. In step eight, transcription reinitiates. All of these
steps require TFs outside of the general TF category for continuation of the transcription
cycle.
Once the appropriate TFs for the particular gene have activated enhancers and
promoters, transcription elongation can begin. It has recently come to light that
divergent RNA transcripts exist at promoters and enhancers (Core et al., 2014).
Activation at an enhancer promoter interaction recruits the general TF machinery to
anti-sense DNA as well as both strands of the enhancer creating unstable RNA (Core et
al., 2014). This further portrays that specificity does not come from the core promoter
where general TFs bind; rather it comes from the binding of regulatory TFs that activate
transcription. Also, events downstream of transcription play an important role in gene
expression. It seems that splicing determines whether RNA becomes stable or unstable.
Thus, differences in enhancer RNA/anti-sense RNA and stable RNA is that stable
transcripts have a binding motif for the U1 splicing complex which allows them to go
through the translation process while unstable transcripts have a binding motif for the
polyadenylation-dependent termination machinery (Core et al., 2014).
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Transcription Factor Binding
TF binding can activate transcription by recruiting the general TFs to the core
promoter or recruit chromatin remodeling enzymes that de-condense the chromatin to
provide TFs access to the DNA (Blackwood and Kadonaga, 1998; Lee and Young,
2000; Struhl, 1998; Workman and Kingston, 1998). Alternatively, protein binding to the
DNA can also lead to repression of transcription by competing for an activator’s binding
site, interacting with an activator or general TF and inhibiting their function, or by
recruiting chromatin remodeling enzymes that condense the chromatin at a promoter or
enhancer (Hanna-Rose and Hansen, 1996; Lee and Young, 2000; Struhl, 1998;
Workman and Kingston, 1998). Different and distinct combinations of TFs regulate
specific genes, repress or activate, and bind proximal and distal regulatory elements
(Gerstein et al., 2012).
TFs typically have DNA binding domains that recognize specific DNA sequences.
There are more than eighty known types of sequence specific DNA binding domains
and those domains with similar amino acid sequences will bind to similar DNA
sequences (Weirauch and Hughes, 2011; Weirauch et al., 2014). These TF binding
sites are conserved in the genome and TF binding exhibits allele specific activity
(Gerstein et al., 2012; Neph et al., 2012).
In vitro binding assays can identify the consensus sequence of many TFs. Yet in
order for TFs to bind to their consensus sequence in the cell, the region may need to be
accessible or nucleosome free, or their may need to be co-binding with other TFs.
Additionally the TF needs to be expressed in the cell type. TF expression correlates to
activity of enhancers and promoters with a TF motif (Ernst et al., 2011). ChIP-seq for
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TFs identifies binding sites in the cell, but does not have the resolution of the in vitro
assays to identify the exact binding sequence (Figure 6). A combination of both assays
can inform the DNA binding properties of TFs. EMSA test allele specific activity of TF
binding. Nuclear extracts mixed with radiolabeled probes containing the major or minor
allele are run on a polyacrylamide gel (Kerr, 1995). If the allele disrupts a TF binding
motif, the gel will show different band patterns between the major and minor allele
probes indicative of changes in TF binding.

Chromatin Structure
As mentioned earlier in the text, histones play a major role in transcription
regulation since they determine the accessibility of the DNA. Chromatin modifiers affect
histone binding therefore specific histone modifications inform the activity of the DNA
bound to that histone (Narlikar et al., 2002). Histone H3 lysine 4 tri-methylation
(H3K4me3) marks DNA at promoters (Bernstein et al., 2005; Dunham et al., 2012; Ernst
et al., 2011; Guenther et al., 2007; Heintzman et al., 2007; Mikkelsen et al., 2007).
Increasing levels of transcriptionally engaged RNA polymerase II, or transcripts that
consistently and stably transcribe, have increased levels of H3K4me3 (Core et al.,
2014). Histone H3 lysine 4 di-methylation (H3K4me2) marks promoters and enhancers
(Bernstein et al., 2005; Ernst et al., 2011; Heintzman et al., 2007). Histone H3 lysine 4
tri-methylation (H3K4me1) marks DNA at enhancers (Dunham et al., 2012; Ernst et al.,
2011; Heintzman et al., 2007). Histone H3 lysine 27 acetylation (H3K27ac) and Histone
H3 lysine 9 acetylation (H3K9ac) marks transcriptionally active DNA (Dunham et al.,
2012; Ernst et al., 2011; Heintzman et al., 2007). Histone H3 lysine 36 tri-methylation
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and Histone H4 lysine 20 mono-methylation mark transcribed DNA (Ernst et al., 2011;
Guenther et al., 2007; Mikkelsen et al., 2007). Histone H3 lysine 27 tri-methylation
(H3K27me3) marks repressed DNA (Dunham et al., 2012; Ernst et al., 2011; Heintzman
et al., 2007; Mikkelsen et al., 2007). Combinations of these histone marks inform
whether the regions are active, weak or poised (Ernst et al., 2011). Promoter and
enhancer states vary between active, weak and poised among different cell types but
the regions of the DNA seem to maintain regulatory potential (Ernst et al., 2011).
Promoters active in one cell type and not another seem to be cell type specific genes
while promoters active in many cell types are metabolic housekeeping genes (Ernst et
al., 2011). Enhancer locations are much more cell type specific than promoters. A gene
active in more than one cell type uses one promoter yet uses a different enhancer in
each cell type (Ernst et al., 2011). ChIP-seq for histone posttranslational modifications
identifies the above mentioned regulatory regions (Figure 6). Due to their cell type
specificity, to identify enhancers that affect a particular disease, the appropriate cell line
must be used.
The opposite of histone binding is regions of open chromatin. Regions of open
chromatin represent regions accessible to TFs and represent enhancers and promoters
as well as insulators, silencers, and locus control regions (Gaszner and Felsenfeld,
2006; Li et al., 1999; Thurman et al., 2012). Thirty percent of distal open chromatin
regions have marks of enhancers therefore the remaining sequences may contribute to
chromatin organization (Heintzman et al., 2007). FAIRE identifies regions of open
chromatin and therefore identifies regions with a potential biological function (Figure 6).
FAIRE utilizes phenol chloroform extraction to separate the DNA, that tightly crosslinks
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to nucleosomes, from the unbound DNA in the aqueous layer (Giresi et al., 2007).
Similar to TF binding, chromatin state differentially binds between maternal and paternal
alleles (Dunham et al., 2012; Ernst et al., 2011).

Figure 6: Regulatory regions and how they are identified. Regulatory regions are
regions of open chromatin, bound by TFs. Modified histones also mark the transcription
activity of DNA. FAIRE-seq identifies regions of open chromatin and ChIP-seq identifies
TFs and modified histones bound to DNA.

3D Structure of the Genome
The genome is not structured in a straight line, rather, it is made of chromatin
loops bringing together enhancers and promoters in transcription factories (Gondor and
Ohlsson, 2009). 60% of promoters associate with one enhancer while 90% of
enhancers associate with one promoter (Zhang et al., 2013). Additionally these
interactions seem to be cell type specific with 60% of interactions occurring in only one
cell line (Sanyal et al., 2012). It seems that each cell type utilizes a different enhancer
for the same promoter (Ernst et al., 2011). Enhancers can loop to target genes up to 1
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Mb away, in rare cases even farther (Jin et al., 2013). The average distance between
interacting promoters and enhancers is 120 kb with almost half of the enhancer
interactions occurring with the nearest promoter (Sanyal et al., 2012).
These enhancer and promoter interactions seem to be pre-formed in
development and subsequent events occur to activate transcription rather than having
dynamic interaction between enhancers and promoters to activate transcription (GhaviHelm et al., 2014; Kulaeva et al., 2012). Interestingly, there seems to be specific pairing
between TFs at enhancers and promoters (Thurman et al., 2012). Possibly specific TFs
for a developing cell work together to pre-form these interactions. Promoter and
enhancer interactions occur at open chromatin sites and not at repressed sites (Sanyal
et al., 2012; Thurman et al., 2012). Looped enhancers and promoters are bound by
paused polymerase and transcription initiates once polymerase is activated for
elongation through recruitment of additional factors (Ghavi-Helm et al., 2014).
Promoters that do not interact with an enhancer have low gene expression levels
(Zhang et al., 2013). Most likely, genes are deemed active during development.
Chromatin conformation capture (3C) identifies enhancer promoter interactions
(Dekker, 2006). In this technique, formaldehyde cross links genomic DNA in live cells to
maintain DNA interactions after cell lysis. Digestion and ligation of genomic DNA
produces linear DNA products of the enhancer and promoter that can be amplified with
specifically designed primers for those regions (Dekker, 2006).
Important, yet less studied, regulatory regions in maintaining the 3D structure of
the genome are insulators and nuclear matrix/scaffold attachment regions (S/MAR).
Both often mark borders between condensed and de-condensed chromatin
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(Gerasimova et al., 2000). Insulators are regions of open chromatin bound by CTCF,
and Cohesin creating chromatin loops that either block a promoter and enhancer
interaction or maintain a promoter and enhancer interaction (Bondarenko et al., 2003;
Kagey et al., 2010; Kulaeva et al., 2012; West et al., 2002). S/MARs are often a region
of open chromatin that binds to the nuclear scaffold and surrounded by CTCF and
H3K27me3 binding (Dunham et al., 2012; Guelen et al., 2008; Keaton et al., 2011;
Mirkovitch et al., 1984; Ohlsson et al., 2001). These regions are also thought to be
important in preventing aberrant enhancer activity and maintaining the 3D structure of
chromosomes (Bushey et al., 2008; Guelen et al., 2008; Keaton et al., 2011; Linnemann
et al., 2009). Reporter assays can identify whether an open chromatin region functions
as an insulator or S/MAR by cloning the region in between an enhancer and promoter
and observing decreased or lack of transcription (Kellum and Schedl, 1992). Isolation of
the nuclear scaffold and DNA digestion and extraction can also identify S/MARs
(Dijkwel and Hamlin, 1999; Keaton et al., 2011; Mirkovitch et al., 1984)
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CHAPTER TWO:
IDENTIFYING FUNCTIONAL SNPS

Note to Reader
Two manuscripts that have been submitted for review include portions of this
chapter.

Introduction
To establish the mechanism by which changes in alleles of SNPs in non-coding
DNA contribute to EOC, we conducted a functional dissection of the 9p22.2 ovarian
cancer susceptibility locus. The most significant SNP for high grade serous EOC
reported initially (rs3814113; P = 2.5 x 10-17) is located 44 kb upstream and 220 kb
downstream of the BNC2 and CNTLN TSS, respectively (Song et al., 2009). The minor
allele [C; MAF = 0.323] was associated with reduced risk of EOC (combined data OR =
0.82; 95%CI = 0.79-0.86). A total of twelve genotyped SNPs within the same linkage
disequilibrium (LD) region (r2 ≥ 0.239; D’ ≥ 0.591) reached genome wide significance (P
< 5x10-8) and mapped to non-coding regions, eight of which are located within intron 2
of the BNC2 gene (Song et al., 2009).
Here, we conducted a comprehensive functional analysis of all SNPs at the locus
in LD with rs3814113 (r2 > 0.3). Since all of these SNPs fall in non-coding regions we
hypothesized that they modify the activity of transcription regulatory elements present in
27

enhancers and promoter regions (Freedman et al., 2011; Monteiro and Freedman,
2013) as these regions are the most common regulatory elements and thoroughly
characterized. We integrated several methods to identify functional SNPs with allelespecific effects on enhancers and promoters operating in OSE and fallopian tube
epithelial (FTE) cells (Coetzee et al., 2015).

Results

Candidate Functional SNPs
In order to identify a comprehensive set of candidate functional SNPs at the
9p22.2 locus, we downloaded all SNPs within 250 kb in LD (r2 ≥ 0.3) with rs3814113 in
the 1000 Genomes Database (http://www.1000genomes.org/) using HaploView (Barrett
et al., 2005). These 134 SNPs are distributed over an 82 kb region ranging from the first
intron of BNC2 to ~44 kb upstream from its TSS (Figure 8A and Table 1).

Table 1: Candidate Functional SNPs
2

Chromosome Position

SNP

r

chr9:16914834-16914835
chr9:16915020-16915021
chr9:16914894-16914895
chr9:16910676-16910677
chr9:16910762-16910763
chr9:16912987-16912988
chr9:16911637-16911638
chr9:16911756-16911757
chr9:16913042-16913043
chr9:16913285-16913286
chr9:16913472-16913473
chr9:16913513-16913514
chr9:16913615-16913616
chr9:16910897-16910898
chr9:16909050-16909051

rs10810671
rs3814113
rs7032221
rs10738467
rs10738468
rs4246134
rs4366169
rs4445329
rs4465052
rs4631563
rs6475092
rs6475093
rs6475094
rs7045767
rs7866677

1
1
1
0.974
0.974
0.974
0.974
0.974
0.974
0.974
0.974
0.974
0.974
0.974
0.949
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Table 1 (Continued)
Chromosome Position
chr9:16914702-16914703
chr9:16916692-16916693
chr9:16908168-16908169
chr9:16907583-16907584
chr9:16911664-16911665
chr9:16857402-16857403
chr9:16905440-16905441
chr9:16909109-16909110
chr9:16891646-16891647
chr9:16889936-16889937
chr9:16911399-16911400
chr9:16911665-16911666
chr9:16912434-16912435
chr9:16912660-16912661
chr9:16912662-16912663
chr9:16915104-16915105
chr9:16913556-16913557
chr9:16913767-16913768
chr9:16910213-16910214
chr9:16913835-16913836
chr9:16858083-16858084
chr9:16878615-16878616
chr9:16878492-16878493
chr9:16876282-16876283
chr9:16877137-16877138
chr9:16894139-16894140
chr9:16881876-16881877
chr9:16887365-16887366
chr9:16882915-16882916
chr9:16881372-16881373
chr9:16915873-16915874
chr9:16909001-16909002
chr9:16873550-16873551
chr9:16874611-16874612
chr9:16900694-16900695
chr9:16900764-16900765
chr9:16863363-16863364
chr9:16891560-16891561
chr9:16891589-16891590
chr9:16892271-16892272
chr9:16914715-16914716
chr9:16856882-16856883
chr9:16914577-16914578
chr9:16898118-16898119
chr9:16896587-16896588
chr9:16848789-16848790
chr9:16903361-16903362

SNP
rs7048397
rs10962693
rs55689948
rs113780397
rs10465044
rs10962643
rs10962679
rs7851204
rs10124837
rs10962662
rs10810665
rs10810666
rs10810668
rs10810669
rs10810670
rs10962691
rs12377389
rs12377421
rs62543587
rs74664507
rs10756819
rs10756823
rs10122763
rs10810652
rs10810655
rs10962668
rs12345776
rs3927680
rs4644350
rs7040151
rs10962692
rs12376998
rs10810650
rs10962650
rs28498684
rs36116821
rs62541919
rs10962664
rs10962665
rs10962666
rs62543619
rs1416742
rs62543618
rs10962672
rs10962670
rs1339552
rs34606230

2

r
0.948
0.922
0.922
0.818
0.719
0.719
0.681
0.672
0.638
0.638
0.626
0.626
0.626
0.626
0.626
0.626
0.626
0.626
0.626
0.622
0.611
0.61
0.607
0.607
0.607
0.607
0.607
0.607
0.607
0.607
0.606
0.596
0.589
0.589
0.589
0.589
0.589
0.586
0.586
0.586
0.586
0.572
0.566
0.563
0.555
0.555
0.555
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Table 1 (Continued)
Chromosome Position
chr9:16899284-16899285
chr9:16904634-16904635
chr9:16905169-16905170
chr9:16906005-16906006
chr9:16906093-16906094
chr9:16906151-16906152
chr9:16906306-16906307
chr9:16906888-16906889
chr9:16906509-16906510
chr9:16853778-16853779
chr9:16851677-16851678
chr9:16847519-16847520
chr9:16851976-16851977
chr9:16864520-16864521
chr9:16884585-16884586
chr9:16907645-16907646
chr9:16908382-16908383
chr9:16885016-16885017
chr9:16901227-16901228
chr9:16881255-16881256
chr9:16901066-16901067
chr9:16903365-16903366
chr9:16865698-16865699
chr9:16907966-16907967
chr9:16862279-16862280
chr9:16904947-16904948
chr9:16905327-16905328
chr9:16903947-16903948
chr9:16904079-16904080
chr9:16904201-16904202
chr9:16904354-16904355
chr9:16904140-16904141
chr9:16904302-16904303
chr9:16904495-16904496
chr9:16904640-16904641
chr9:16904704-16904705
chr9:16904845-16904846
chr9:16906358-16906359
chr9:16907996-16907997
chr9:16846259-16846260
chr9:16846322-16846323
chr9:16907674-16907675
chr9:16903849-16903850
chr9:16849603-16849604
chr9:16845725-16845726
chr9:16843012-16843013
chr9:16870181-16870182

SNP
rs62543561
rs62543578
rs62543579
rs62543581
rs62543582
rs62543583
rs62543584
rs62543585
rs72713890
rs10810647
rs4961501
rs7046326
rs7868157
rs2153271
rs10810657
rs181552334
rs80039758
rs12350739
rs13300853
rs7025549
rs62543565
rs10738466
rs12379183
rs117224476
rs7861573
rs10756835
rs12344726
rs7029285
rs7032175
rs7032420
rs7032581
rs7032644
rs58691828
rs7033061
rs7033084
rs7033194
rs7033354
rs7868583
rs77795022
rs1339547
rs1339548
rs76718132
rs10810661
rs10962641
rs10810645
rs4961498
rs62541922

2

r
0.555
0.555
0.555
0.555
0.555
0.555
0.555
0.555
0.555
0.541
0.541
0.541
0.541
0.539
0.528
0.527
0.516
0.508
0.501
0.481
0.475
0.451
0.445
0.44
0.426
0.425
0.425
0.425
0.425
0.425
0.425
0.425
0.425
0.425
0.425
0.425
0.425
0.425
0.422
0.391
0.391
0.379
0.37
0.37
0.346
0.336
0.317
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Table 1 (Continued)
Chromosome Position
chr9:16895577-16895578
chr9:16902523-16902524
chr9:16907620-16907621
chr9:16846110-16846111
chr9:16863542-16863543
chr9:16868379-16868380
chr9:16868957-16868958
chr9:16873534-16873535
chr9:16874877-16874878
chr9:16876735-16876736
chr9:16877787-16877788
chr9:16881345-16881346
chr9:16883317-16883318
chr9:16858568-16858569
chr9:16872322-16872323
chr9:16864075-16864076
chr9:16889022-16889023
chr9:16854366-16854367
chr9:16852452-16852453
chr9:16861204-16861205
chr9:16861507-16861508
chr9:16865290-16865291
chr9:16870500-16870501
chr9:16877422-16877423
chr9:16885463-16885464

SNP
rs12551733
rs4961503
rs9697099
rs10962638
rs10962645
rs10962647
rs10962648
rs10962649
rs10962652
rs10962653
rs10962656
rs10962658
rs10962659
rs11788047
rs11789875
rs11792249
rs12376099
rs12379687
rs62541877
rs62541878
rs62541879
rs62541920
rs62541923
rs62541926
rs77507622

2

r
0.301
0.301
0.301
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3

Functional Analysis of SNPs
Now that a set of candidate functional SNPs have been identified through genetic
means, molecular biology techniques identify SNPs with a biological function. Those
SNPs with a biological function most likely affect disease. Here we map SNPs to
regulatory elements marked by histone markers and open chromatin as well as
measure their transcription activities in luciferase assays and EMSA.
Mapping SNPs to regulatory elements. Since all 134 SNPs in the candidate
functional set are located in non-coding regions, multiple functional assays are needed
to identify regions of transcriptional regulatory activity. First we integrated FAIRE-seq,
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and ChIP-seq for H3K27Ac and H3K4Me1, histone markers for active chromatin and
enhancers, respectively from Coetzee et al. (Coetzee et al., 2015; Ernst et al., 2011;
Heintzman et al., 2007). We generated chromatin landscape profiles at the 9p22.2
locus (Figure 8A) from cell lines postulated to be the origins of high grade serous
ovarian cancer and serous ovarian cancer cell lines.

Table 2: Twenty-two SNPs associated with ovarian cancer risk overlap with areas
of regulatory activity. SNPs highlighted in dark blue have an r2 > 0.8 to rs3814113.
SNPs in blue have an r2 = 0.5 - 0.8. SNPs in light blue have an r2 = 0.3 - 0.5.
Region
1
2
3
4
5
6
7

chr9 Coordinates
Tile
16,837,392-16,838,723
16,848,158-16,848,790
16,850,432-16,851,014
16,852,717-16,853,479
16,857,377-16,857,907
T5
16,860,790-16,861,348
T6
16,863,768-16,874,127
T7.1
T7.2
T7.3
T7.4 & T7.5
T7.6
T7.7
T7.8

8

Reference
Allele

R2

rs10962643

A

C

0.719

rs62541878

T

A

0.3

rs11792249
rs2153271
rs62541920
rs12379183
rs10962647
rs10962648
rs62541922
rs62541923
rs11789875
rs10962649
rs10810650

G
T
A
G
G
C
C
A
A
T
T

T
C
G
A
T
G
T
C
G
C
C

0.3
0.539
0.3
0.445
0.3
0.3
0.317
0.3
0.3
0.3
0.589

rs10810657
rs12350739
rs77507622

A
A
G

T
G
A

0.528
0.508
0.3

rs113780397
rs9697099
rs181552334
rs76718132
rs117224476
rs77795022

A
A
G
T
G
G

G
T
A
C
T
T

0.818
0.301
0.527
0.379
0.44
0.442

16,899,790-16,900,338
16,901,238-16,902,039
16,907,559-16,908,180

T11

12

Effect
Allele

16,883,570-16,885,692
T8

9
10
11

SNP Name

16,915,387-16,915,739
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FAIRE and ChIP-seq profiles revealed twelve regions showing evidence for
enhancer activity in at least one ovarian cell line (Figure 8A). Twenty-two candidate
functional SNPs (Table 2) overlapped with five regions containing FAIRE or ChIP-seq
features (Figure 8A).
Development of Enhancer Scanning method. Several SNPs overlapped with
regions of activity at the 9p22 locus. To eliminate non-causal SNPs in an accelerated
fashion, we developed a streamlined method that can systematically scan for regions
with regulatory activity in a cell line of choice and can be scaled-up to study relatively
large genomic regions (100-500 kb). The method takes advantage of online
bioinformatics tools and combines a PCR-based generation of tiling clones spanning the
region with high efficiency recombination cloning.
Experimental Design. The complete procedure is depicted in Figure 7. To
reiterate, we start with a genomic region identified by a GWAS as associated with risk
for a certain condition (Figure 7) and to reiterate we assume that the tagging SNP may
not necessarily represent the functional SNP. Next, in order to capture the variation in
the locus we can use linkage disequilibrium (LD) structure information and retrieve all
SNPs in (LD) with the tagging SNP (Figure 7) (Carlson et al., 2004; Hazelett et al.,
2014). As a rule of thumb, we retrieve sets of SNPs in LD in 1000 Genomes Project with
r2 ≥ 0.3, ≥0.5, or ≥0.8. These thresholds are arbitrary and serve as a guideline for the
investigator to decide which set to pursue further analysis appropriate for the resources
and time available.
With the regions of interests marked by enhancers defined, we next generate
tiles by PCR spanning the regions marked by enhancers with each tile of approximately
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2 Kb (Figure 7). This size is a compromise between having to generate the least
amount of tiles to cover a region and efficient and reproducible PCR amplification.
Regions with repetitive sequences may need smaller tiles to facilitate amplification. The
PCR primers used are designed to include attR sequences to mediate recombinational
cloning into destination vectors, pGL3-LRF and pGL3LRR, that contain a luciferase
gene driven by a basal promoter (Figure 7). Using the Gateway® Vector Conversion
System, we converted the pGL3-Promoter vector (Promega) to a Gateway® destination
vector by inserting a blunt-ended cassette of the ccdB gene and the chloramphenicol
resistance gene flanked by attR1 and attR2 sites into a SmaI site of pGL3-Promoter
vector. Two recombinant vectors, carrying the cassette in each orientation, pGL3-LRF
and pGL3-LRR, are then used to clone individual tiling clones by recombination.
Plasmids containing tiling clones in both orientations are then transfected in an
appropriate cell type and activity of luciferase is measured and compared with the
corresponding pGL3-LR destination vector (Figure 7).
Although enhancers are expected to operate independent of orientation and
position relative to the target promoter (Khoury and Gruss, 1983), because the relative
position of the binding site in relation to the promoter of the reporter may influence
expression, tiles should be tested in both cloning orientations.
True functional SNPs are also expected to show allele specific differences in
enhancer activity. Risk alleles may create or disrupt a specific binding site therefore it is
recommended to test both alleles for each SNP. Different alleles can be introduced in
the tiles using Quick Change PCR mutagenesis (Braman et al., 1996).
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Choice of template, tile verification, and host cell. Once the region of interest is
defined we generate tiles by PCR using human genomic DNA or a Bacterial Artificial
Chromosome (BAC) clone containing the region of interest (Figure 7). In our experience
the latter provides a more robust option to amplify the tiles. It is expected that the BAC
is likely to contain the major allele for the SNPs, but could represent the minor allele. In

Figure 7: Luciferase assay protocol. Here we designed a semi-high-throughput assay
that utilizes transcription reporter plasmids to test several potential regulatory elements
for transcription activity.

addition, depending on the number of loci being studied and the size of regions to be
analyzed there could be hundreds of tiling clones to be processed simultaneously
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increasing the chance of sample mix-ups. Thus, it is useful to sequence a sample (or
all) of the clones to confirm their identity and to determine the correct allele being
tested.
Ideally the host cell for the transfection should represent a tissue compartment
relevant for the disease under study. For example, cells for normal intestinal crypts
when studying colorectal cancer. However, primary cells might be difficult to transfect
and immortalized or cancer cells may provide an alternative, but the use of these cells
lines should be kept in mind when interpreting the results.
Controls. Several controls are advisable to guarantee data quality and wise use
of resources and reagents. We found that because in each experiment a large number
of luciferase measurements are going to be made, it is important to have a monitor of
whether the transfection has worked before processing samples. We recommend the
use of a parallel transfection with a GFP expression vector of choice and when there is
no detectable GFP-positive cell we do not proceed to lyse cells and measure luciferase.
We also include a positive control (pGL3-Control Vector containing with a SV40
enhancer) and expect its activity to be consistent across transfections (10-20X the
negative control in the experiment, for example). Eight replicates are performed for each
tile in each orientation. The negative controls used are the plasmids that only include
the recombination cassette in both orientations and are compared to the tested tiles of
the same orientation. An additional control derived from the region being studied is also
recommended and can be designed by identifying a region with no chromatin markers
indicative of activity.
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Statistical analysis. Results from transfections with individual tiles are analyzed in
eight replicates. This number allows for the generation of box whisker plots and
maximizes the 96-well setup but investigators might want to scale it down to reduce
costs. Raw readings from firefly (Photinus pyralis) luciferase are normalized against an
internal Renilla reniformis luciferase control driven by a minimal promoter, pRL-TK
(Renilla luciferase driven by thymidine kinase promoter) to adjust for differences in
transfection efficiency in different wells. Next, we set the negative control (pGL3-LRF
and pGL3-LRR empty vectors) as the reference and results are transformed to fold over
the negative control. Statistical analysis is performed by comparing the exact means
and p ≤ 0.05 is considered significant. When testing a large number of tiles, a multiple
testing correction can be applied (for example, p≤ 0.05/number of tiles being tested).
Alternatively, a less stringent false discovery rate can also be applied for prioritization.
However, we feel that due to the stage of SNP analysis in which this assay is being
performed it would be unwarranted to apply multiple testing corrections as true positive
clones with small effects might be discarded. Additional more stringent tests are
subsequently applied to the tiles (for example, allele-specific differences, activity in
EMSA, etc.) to weed out false positive hits.
Anticipated results. At the end of the protocol we anticipate that the investigator
will have generated tiles representing the genomic region of interest and will have
identified those that contain regulatory regions capable of activating transcription of a
heterologous reporter gene in the cell line of choice. These tiles can then be reduced to
narrow down the region and they can be mutagenized to test whether different alleles of
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SNPs contained in the tile have specific effects. The results provide an empirical map of
regulatory activity operating in the locus for the cell lines tested.
Limitations. The enhancer scanning method presented here is based on the use
of a plasmid-based reporter gene to detect regions in the genomic DNA with
transcriptional regulatory activity. As other naked DNA-based assays (such as EMSAs)
it identifies sequences present in the DNA that have the ability to recruit and bind
transcriptional regulators. It is conceivable that the underlining DNA (exposed in the
plasmid-based assay) that carries the activity may, in certain chromatin contexts, be
hidden by tight nucleosome packing, repressive chromatin features and DNA
methylation. Thus, some tiles may be false positive hits.
The sensitivity of the method presented here is dependent on transfection
efficiency and cells that are difficult to transfect, or experiments in which transfection is
sub optimal, may not identify all tiles with activity. Use of a set of internal controls
greatly minimizes false negatives due to transfection failures. The ability of the
enhancer to activate transcription of a cognate promoter region depends of the
formation of an adequate DNA loop between the enhancer and promoter (Plank and
Dean, 2014). Thus, it is conceivable that even when testing both cloning orientations in
a plasmid context, an optimal loop may not form between the region and the promoter
leading to false-negative results. Our data suggests that the fraction of false negatives
due to the plasmid context is small.
Finally, it is unclear to what extent the detection of a regulatory activity using a
heterologous promoter affects the results. It is possible that the enhancer-promoter
interaction depends on binding factors or other promoter features (biochemical
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compatibility) (van Arensbergen et al., 2014) that are not found in the SV40 promoter. In
this case, the enhancer scanning method may not properly identify the region. Thus, we
suggest that strong candidates be tested also against the promoter of candidate target
regions in the locus.

Figure 8: Functional annotation identifies candidate functional SNPs overlapping
with regions of regulatory activity in ovarian cells. A. Within the region of the 9p22
locus containing linked SNPs, twelve regions contain FAIRE peaks (gray), H3K27Ac
peaks (orange), and/or H3K4Me1 peaks (maroon) in iOSE, iFTSE, and ovarian cancer
cells. Regulatory regions highlighted in yellow do not overlap with candidate functional
SNPs. Regions highlighted in red overlap with candidate functional SNPs. Blue bars
represent location of 2 kb tiles cloned into luciferase reporter vectors. B. Box and
whisker plots show the luciferase activity from duplicate experiments with 8 biological
replicates of each tile in both orientations. Asterisks denote tiles exhibiting significant
transcription activity compared to a control tile (C) located in a genomic region in the
locus inactive in ovarian cells as judged by features in the figure. Tiles moved forward in
the functional assays are colored red.
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Mapping SNPs to regions of enhancer activity. Using the Enhancer Scanning
method, we tested twelve genomic tiles (~2 kb each) (Figure 8A), in both orientations,
spanning the five functional regions cloned upstream of the SV40 promoter driving
expression of luciferase. We also tested two additional tiles: one overlapping with the
most significant SNP (T12.1) and a control tile devoid of enhancer activity as judged by
FAIRE and ChIP-seq data (Figure 8A, Tile C).
Tiling clones were transfected in IOSE4cMYC ovarian cells (an early stage in vitro
transformation model of ovarian cancer) (Lawrenson et al., 2010) and luciferase levels
were determined 24h post transfection. Tiles in regions 6 (T6), 7 (T7.2, T7.3, T7.6), and
8 (T8) containing 9 candidate functional SNPs displayed significant activity in either
orientation (two tailed t-test p<0.05 compared to the control tile C, repeated in duplicate
tests) (Figure 8B).

SNPs with Allele Specific Effects
SNPs with allele specific enhancer activity. We further hypothesized that
SNPs likely to have a functional impact will display allele-specific effects. Thus, we
performed site directed mutagenesis to switch from the reference to the effect allele in
tiles with significant luciferase activity and compared the activity of different alleles.
Significantly different activity between reference and effect allele was found for seven
SNPs in three regions, T6 (rs62541878), T7 (rs62541920, rs12379183, rs1092647), and
T8 (rs77507622, rs10810657, rs12350739), which were retained for further analysis
(Figure 9A).
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Figure 9: SNPs showing allele-specific activities. A. Luciferase assays reveal
significant allele specific differences in transcription activation for rs62541878,
rs62541920, rs12379183, rs1092647, rs77507622, rs10810657, and rs12350739 as
indicated by red asterisks. Reference and effect allele tiles are shown as black and gray
box and whiskers, respectively. B. EMSA showing allele specific differences in mobility
between the reference and effect alleles. SNPs in Regions 7, 8, and 11 display
differences in complex formation between the reference and effect alleles. SNPs with
allele specific differences are indicated by red text.
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Allele specific activities in electrophoretic mobility shift assays. We
conducted electrophoretic mobility shift assays (EMSA) (Kerr, 1995) using fourteen 41mer probes to interrogate both alleles for each of the seven SNPs listed above and
located in regions 6, 7 and 8 (Figure 9B). Tile 11 had significant transcription activity in
only one reporter experiment but two SNPs within the region (rs113780397 and
rs181552334) are correlated with r2 of 0.818 and 0.5 respectively, (the highest r2 values
of all candidate functional SNPs (Table 2)) and so four additional probes were tested.
We also tested rs3814113, the most significant SNP, for allele-specific effects.
We obtained nuclear extracts from IOSE4cMYC cells growing in log phase and incubated
with oligonucleotide probes containing the reference or the effect allele. EMSA revealed
allele specific effects for rs12379183, rs62541920 (Region 7), rs12350739, rs77507622
(Region 8) and rs181552334 (Region 11) (Figure 9B) indicating that five SNPs in three
regions at the 9p22.2 locus are functionally relevant.

Summary
The two SNPs in Region 7 reside in an approximately 7kb region that includes
the TSSs for two BNC2 transcripts (Figure 11 and Figure 12A) denoted by FAIRE-seq
and H3K4me1 ChIP-seq data in ovarian cells, and ENCODE layered H3K4me3
(promoters) ChIP-seq data (Figure 11 and Figure 12A). This region is the major BNC2
promoter, implicating BNC2 as a candidate mediator of ovarian cancer susceptibility at
the 9p22.2 locus (Figure 11).
Region 8, containing two SNPs with allele specific activity in luciferase assays
and EMSA, overlaps with FAIRE-seq and ChIP-seq data in ovarian cells with features
42

Figure 10: Conservation and S/MAR predicted sequences within the locus. A. This
snapshot from the genome browser for the region containing linked SNPs includes
tracks for Phylop, PhastCons scoring for conservation and alignment of DNA sequences
among several vertebrates. Interestingly, region 7 and 8 have peaks of conservation for
both scoring systems while regions 6 and 11 lack a conservation signal. B. Region 11
contains sequences highly predicted by MAR-Wiz to attach to the nuclear
scaffold/matrix compared to the rest of the locus. The intensity of prediction was driven
by the Origin of Replication Rule and the A-T Richness Rule.
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indicative of an enhancer (Figure 11 and Figure 8A). Region 11 overlaps with FAIREseq data in ovarian cells and one SNP displayed allele-specific effects in EMSA
experiments. Yet, it lacked ChIP-seq data for enhancer histone marks and had weak
evidence for enhancer activity in luciferase assays. Interestingly, the region contains a
sequence predicted to bind to the nuclear scaffold/matrix (Figure 11 and Figure 10) by
MAR-Wiz (http://genomecluster.secs.oakland.edu/MarWiz/). The FAIRE-seq peak
indicates lack of nucleosome formation at region 11 (Figure 10 and Figure 8A)
consistent with observation of scaffold/matrix attachment regions (S/MARs) in plant and
human cells (Keaton et al., 2011; Pascuzzi et al., 2014). The region is also A/T rich, a
common feature of S/MARs (Keaton et al., 2011). Although S/MARs are poorly
characterized functionally they have been suggested to regulate adjacent genes
(Linnemann et al., 2009).

Figure 11: Summary of location of SNPs with most compelling evidence for
function. Five out of 134 candidate functional SNPs have the most compelling
evidence for function. Two reside within the promoter of BNC2. Two reside within an
enhancer and one resides in a putative S/MAR.

We are continuing to investigate the potential S/MAR by performing a nuclear scaffold
extraction (Dijkwel and Hamlin, 1999; Keaton et al., 2011) followed by qPCR for region
11. Additionally ChIP for Lamin B1, a nuclear matrix protein, and CTCF may also give
additional evidence for S/MAR sites (Guelen et al., 2008; Keaton et al., 2011). Even
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though enhancers make up the majority of regulatory elements in the genome, other
potential regulatory elements such as insulators and S/MARs need further
characterization since they may affect disease such as we have shown in this chapter.

Materials and Methods

Candidate Functional SNPs
In order to identify a set of candidate functional SNPs in the locus we
downloaded all SNPs within 250 kb of rs3814113, the SNP originally associated with
ovarian cancer risk (Song et al., 2009) from the 1000 Genomes Project (v3) (Abecasis
et al., 2012). The data was uploaded into Haploview. SNP retrieval was done by running
Tagger only including rs3814113 and capturing all SNPs within 250 kb of rs3814113
resulting in 134 SNPs with an r2 > 0.3.

Cell Lines and Cell Type-specific Datasets
The contribution of various cell and tissue types for the origin of different invasive
EOC subtypes, and their molecular profiles indicate that histotypes of EOC should be
considered different diseases (Berns and Bowtell, 2012). Subtype analysis of the
association of the most significant SNP (rs3814113) revealed a stronger association
when the analysis was restricted to high grade serous tumors, marginally associated
with endometrioid tumors and no evidence of association was seen for mucinous or
clear cell carcinoma, although non-serous subtypes have relatively small sample sizes.
Thus, we chose to use, whenever possible, cell lines and datasets originating from
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ovarian surface and fallopian tube epithelium. Experiments were conducted in two
immortalized normal ovarian surface epithelial cell lines, iOSE4 and iOSE11
(Lawrenson et al., 2009), two immortalized normal fallopian tube surface epithelial cells
(iFTSEC33 and iFTSEC246). In addition, we used a normal epithelial ovarian cell line
immortalized with hTERT and transformed with MYC called IOSE4cMYC (Lawrenson et
al., 2010) and two ovarian cancer cell lines, CaOV3 considered highly likely high grade
serous carcinoma by molecular profiling (Domcke et al., 2013) and UWB1.289 (BRCA1null)(Dellorusso et al., 2007). (Dellorusso et al., 2007).
Immortalized ovarian cells were grown in media with a 1:1 ratio of
MCDB105/Medium 199, 15% Fetal Bovine Serum (FBS), 10 ng/mL Epidermal Growth
Factor, 0.5 µg/mL hydrocortisone, 5 µg/mL insulin, and 34 µg/mL Bovine Pituitary
Extract. For 4C2 cells medium was complemented with 2 µg/mL Blasticidin.

FAIRE-Seq and ChIP-Seq for Histone Modifications
FAIRE-Seq and ChIP-Seq for Histone H3 Lysine 27 Acetylation and Histone H3
Lysine 4 Monomethylation was performed in iOSE4, iOSE11, iFTSEC33, iFTSEC246,
UWB1.289, and CaOV3 (Coetzee et al., 2015).

Enhancer Scanning
A series of genomic tiles of ~2 kb spanning regions with evidence of regulatory
activity in experiments for FAIRE-Seq and ChIP-Seq for Histone modifications and
containing significantly associated SNPs were generated by PCR amplification with
KOD (Millipore) or Taq Polymerase (Qiagen) using 50 ng of bacterial artificial
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chromosome (BAC) Clone RPCI-11-185E1 (Empire Genomics) as template. Tiles were
cloned in both a forward and reverse orientation upstream of the SV40 promoter by
recombination in the firefly luciferase reporter vector pGL3-Pro-attb vector designed to
test for enhancer regions. It is a modification of pGL3-Promoter (Invitrogen) adding attb
sites surrounding the cddb gene.
Each tiling clone (100 ng) was co-transfected in eight replicates into IOSE4cMYC
cells with 10ng of pRL-CMV (Promega), an internal control expressing Renilla
luciferase, per well of 96 well plates of IOSE4cMYC cells. Luciferase activity was
measured 24 hours post transfection by Dual Glo Luciferase Assay (Promega). Quick
Change II XL Site Directed Mutagenesis Kit (Agilent) was used to mutate the tiles from
the reference to the effect alleles.
Firefly Luciferase counts are normalized by Renilla luciferase counts in each
sample. Each read is then divided by the average normalized read of TC (the control tile
devoid of any activity-associated chromatin features) for scanning experiments, or by
the normalized read of the plasmid with the reference allele in allele-specific
experiments to generate the normalized fold change over the control. Tiles with
significantly (two tailed t-test <0.05) higher luciferase counts than the control tile (TC) in
two independent experiments in both orientations were tested for allele specific effects.
Tile T7.2 was significant in only one experiment for the forward orientation but its
reverse orientation was significant in both experiments and was thus included. For
allele-specific luciferase assays, tiles with the effect allele were considered significant if
the luciferase counts were significantly higher (p-value <0.05) in one independent
experiment than the tile with the reference allele.
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Genome Browser
Bed files using the hg19 genomic positions were created for the ChIP-seq and
FAIRE-seq data (Coetzee et al., 2015), as well as a list of the candidate functional
SNPs, and enhancer scanning tiles. These bed files were uploaded to the genome
browser by clicking manage custom tracks followed by add custom tracks in our own
session file of the genome browser. We could then visualize and overlap SNPs with the
regulatory elements and design tiles that overlap with the regulatory elements
containing SNPs. Under this session we can also include tracks from the genome
browser.

Electrophoretic Mobility Shift Assays
Nuclear extracts were obtained from IOSE4cMYC cells at 70-90% confluence.
Cells were harvested, pelleted at 450 g for 5 minutes, and suspended gently in 1X Lysis
Buffer (10 mM HEPES pH7.9, 1.5 mM MgCl2, 10 mM KCl, 10 mM DTT, protease
inhibitor cocktail), and incubated on ice for 15 minutes. The cell suspension was
centrifuged for 5 minutes at 450 g and the pellet was re-suspended in 1X Lysis Buffer.
The cells were disrupted using a syringe with a narrow gauge (No. 27) and nuclei were
pelleted by centrifugation at 11,000 g for 20 minutes followed by re-suspension in 1X
Extraction Buffer (20 mM HEPES pH7.9, 1.5 mM MgCl2. 0.42 M NaCl, 75% Glycerol, 10
mM DTT, protease inhibitor cocktail) and shaken for 30 minutes. The nuclear extracts
were cleared by centrifugation at 21000 g, 4°C.
Single stranded DNA (ssDNA) oligonucleotides containing the reference or effect
allele in the center of the 41-mer probe were synthesized (Invitrogen). The probe is
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prepared by heating complementary ssDNA to 100°C in Elution Buffer (10 mM Tris·Cl,
pH 8.5) and annealed by slowly decreasing the temperature. Annealed probes (10
pmol) were labeled with γ32P-dATP using T4 polynucleotide kinase (NEB) for 1 hour at
37°C, followed by 30 minutes at 65°C. The unincorporated dNTPs were removed using
the Qiaquick nucleotide removal kit (Qiagen). For each binding reaction 10 µg of nuclear
extract were mixed with 1 µL of labeled probe in 1 X Binding Buffer (10 mM Tris, 50 mM
KCl, 1 mM DTT; pH 7.5) with 1 µg poly dI-dC and incubated for 20 minutes, room
temperature. Loading Buffer (5X) was added to the binding reaction and loaded in 6%
native polyacrylamide gel. The gel was pre-run for at least 1 hour at 100V, loaded and
electrophoresed at 80V overnight.
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CHAPTER THREE:
IDENTIFICATION OF TARGET GENE

Note to Reader
A manuscript that has been submitted for review includes portions of this
chapter.

Introduction
In this chapter, we next identified the major target gene regulated by the
candidate functional SNPs at the 9p22.2 ovarian cancer susceptibility locus. We tested
whether candidate target genes are functionally and physically associated with the
previously identified functional SNPs. The closest gene to these SNPs is BNC2. BNC2
expression has been compared between immortalized normal ovarian epithelial cell
lines and ovarian cancer cell lines and BNC2 expression decreases in cancer cell lines
compared to normal (Goode et al., 2010). Additionally, immortalized ovarian epithelial
cells subjected to transformation with c-MYC and KRAS also displayed reduced
expression of BNC2 compared to the parental cell lines (Goode et al., 2010) implicating
BNC2 as a potential target for ovarian cancer predisposition as well as a potential tumor
suppressor. Since enhancers can loop to target genes at an average of 1 Mb away (Jin
et al., 2013) only looking at the nearest gene would not be the most agnostic approach.
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Results

BNC2 and CNTLN as Candidate Target Genes
Transcription activity at candidate gene promoters. Next, we examined all
four genes (c9orf92, BNC2, CNTLN and SH3GL2) within 1 MB at either side of the
region defined by the candidate SNPs (Figure 12A). We first identified their promoters
by the presence of layered H3K4me3 in the vicinity of TSSs on seven non-ovarian cell
lines from ENCODE (Integrated Regulation from ENCODE) (Figure 12A). The
H3K4me3 promoter mark does not depend on cell type specificity as much as
enhancers but rather promoters resides at similar locations across all cell types
(Dunham et al., 2012). Next, we determined whether the gene was expressed in
ovarian cell lines by examining the presence of H3K27ac as a surrogate marker of
active promoters as well as transcript levels from RNA-sequencing data for ovarian and
fallopian tube epithelial cells (Figure 12B). While marks in the BNC2 and CNTLN
promoters, combined with RNA-seq data indicate that they are expressed in ovarian
cells, we saw little evidence of expression for c9orf92 and SH3GL2 (Figure 12B).
Taken together, our results indicate that BNC2 and CNTLN are the strongest candidate
gene targets at this locus.
Expression Quantitative Trait Loci (eQTL). Measurement of BNC2 and
CNTLN mRNA levels in ovarian tissue binned by genotype (AA, AT, or TT) (eQTL) was
performed to test whether the genotype at rs3814113 correlates to expression of genes
within the 1 Mb region surrounding the SNP. There was no correlation between the SNP
and expression changes of BNC2 or the next closest gene, CNTLN. eQTL analysis was
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Figure 12. Functional SNPs influence transcription of BNC2. A. A snapshot from
the genome browser displays UCSC genes as well as FAIRE peaks (gray), H3K27Ac
peaks (orange), and/or H3K4Me1 peaks (maroon) in iOSE, iFTSE,, and ovarian cancer
cells generated in the laboratory. The four genes within the region considered as
potential target genes for ovarian cancer susceptibility include c9orf92, BNC2, CNTLN,
and SH3GL2. ENCODE H3K4me3 peaks (purple), used to identify the promoters for
these four genes (highlighted in yellow). H3K27ac tracks (orange) inform the extent to
which these promoters are active and show that BNC2 and CNTLN promoters are
active in ovarian cells while c9orf92 and SH3GL2 are less active. B. RNA-seq for these
four genes indicates the presence of transcripts for BNC2 and CNTLN but not for
SH3GL2 and c9orf92. C. 3C analysis indicates that Region 8 (left) interacts with the
BNC2 promoter while region 11 (right) does not show a significant interaction compared
to the adjacent site. Anchor regions for 3C are highlighted in red.
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also performed using TCGA ovarian tumor data. In this dataset the genotype at
rs3814113 does not correlate to expression of BNC2 or CNTLN. eQTL was also
performed genome wide among TCGA ovarian tumor data and not a single gene had
expression level significantly correlating to the genotype. Since the SNP does not
correlate to expression in normal or tumor tissue there may be context specific gene
regulation of BNC2 and cannot be visualized from these samples. A null eQTL has also
been seen for TFs MYC, ESR1, and KLF4 with breast cancer associated SNPs even
though other methods point to these genes as likely targets (Li et al., 2013). It is
presumed that TFs are tightly regulated. Therefore a positive eQTL will not be
observed.

Region 8 is in Physical Proximity to the TSS of BNC2 in Ovarian Cells
We used Chromatin Conformation Capture (3C) to identify which promoters in the locus
interact with Region 8. In iOSE11 cells, Region 8 displays more frequent interactions
with the canonical BNC2 promoter compared to an adjacent restriction site (Figure
12C). Region 11 showed no significant interactions with the promoters for the canonical
and alternative BNC2 transcripts, or with the CNTLN promoter (Figure 12C). Taken
together the data indicate that Region 7 and 8 are involved in the regulation of the
transcription of BNC2. The modules in Region 7 affect the major promoter of BNC2 and
the module in Region 8 is a distal regulatory enhancer which physically interacts with
the BNC2 promoter.
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Summary
In summary, we deduced from four candidate functional SNPs, that BNC2 is the
target gene of this locus. Transcription activity at promoters measured by ChIP-seq for
H3K27ac and presence of transcripts measured by RNA-seq narrowed our candidates
to BNC2 and CNTLN. Finally, physical interactions between the enhancer and promoter
of BNC2 measured by 3C identified our final candidate (Figure 13).

Figure 13. Summary of locus target genes. BNC2 is the most likely target of the two
SNPs in its promoter. The SNPs within the enhancer and S/MAR could possibly
regulate genes within a 1 Mb region. Of the four genes, CNTLN and BNC2 were the
only ones expressed. The enhancer containing two functional SNPs looped to the
promoter of BNC2 and not the promoter of CNTLN.
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Materials and Methods

eQTL Analysis
eQTL analysis was performed as described elsewhere (Pharoah et al., 2013).

3C
iOSE11 cells grown to approximately 80% confluence in media with a 1:1 ratio of
MCDB105/Medium 199, 15% Fetal Bovine Serum (FBS), 10 ng/mL Epidermal Growth
Factor, 0.5 µg/mL hydrocortisone, 5 µg/mL insulin, and 34 µg/mL Bovine Pituitary
Extract were trypsinized and re-suspended in 1% formaldehyde. Fixed cells were
pelleted and then re-suspended with 0.125 M glycine-PBS solution. Cells were lysed in
500 µL cold lysis buffer (10 mM Tris HCl pH 8.0, 10 mM NaCl, 0.2% NP40, Protease
Inhibitor). After centrifugation the remaining pelleted nuclei was rinsed with 500µL New
England Biolabs Buffer 2 (NEBuffer2), then re-suspended with 200 µL NEBuffer2. An
additional 1320 µL NEBuffer2 was added along with 168 µL 1% SDS and incubated at
65°C for 12 minutes, followed by addition of 176 µL 10% Triton X-100. EcoR1 (375
units) was added in 150 µL NEBuffer2 and incubated for 24 hours at 37°C.
To stop digestion, 86 µL of 10% SDS was added and samples were incubated for
30 minutes at 65°C. Cells (4 x 107) were pooled and mixed with 7.44 mL of ligation
buffer (1x T4 Ligase Buffer (NEB) 1% Triton-X 100, 1 mg/mL BSA) followed by the
addition of 10 µL of T4 DNA ligase. Samples were incubated for 1 to 5 days at 16°C and
then digested with proteinase K and de-cross-linked at 65°C overnight. DNA was then
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extracted with Phenol-Chloroform (Sigma) and ethanol precipitated. Re-hydrated DNA
was then desalted with Microcon Ultra Cell YM -100 and eluted.
qPCR was performed by using Taq Polymerase PCR Kit (Qiagen) and Syto9
(Life Technologies) with 30 ng of DNA 1X Taq Buffer, 0.2 mM dNTPs, 0.25 µM Primers,
0.1 µL Taq Polymerase, 30 ng of DNA library, 5 µM Syto9; 95°C for 15 minutes, 50
cycles at 94°C for 20 seconds, 60°C for 1 minute. Samples were run using FAM
Spectrum on and Applied Biosystems 7900 HT Fast Real Time PCR System. EcoR1
digested BACs (RPCI-11-185E1 Empire Genomics, RPCI-11-179K24 Life
Technologies, RPCI-11-106G11 Life Technologies) for the region were used for the
standard curve (Hagege et al., 2007). Interactions were calculated as a percentage of a
restriction site directly adjacent to the bait restriction site. Sites with significantly higher
frequency of interaction than the site adjacent to the anchor were considered significant.
3C was performed with two biological replicates and three technical replicates.
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CHAPTER FOUR:
FUNCTIONAL ANALYSIS OF BNC2

Note to Reader
A manuscript that has been submitted for review includes portions of this
chapter.

Review of Basonculin 2
Taken together, the functional data points to BNC2 as the most likely candidate
target gene of the causal SNPs at the ovarian cancer susceptibility locus.

Identification of Basonuclin 2 and comparison to Basonculin 1
A chicken and mouse EST database search for homologs of Basonuclin 1 (bnc1)
identified the novel gene bnc2 (Romano et al., 2004; Vanhoutteghem and Djian, 2004).
Bnc1 expresses in epidermal keratinocytes and reproductive germ cells of mouse testis
and ovary (Mahoney et al., 1998; Tseng and Green, 1992; Yang et al., 1997). BNC1, a
nuclear ZF protein and TF, binds to and activates transcription of ribosomal RNA
promoters while also localizing to areas typical of RNA polymerase I TFs (Iuchi and
Green, 1999; Tian et al., 2001; Tseng et al., 1999). ZF domains have specific amino
acids within the alpha helix of the domain that interact with specific nucleotides within
the major groove of the DNA helix (Wolfe et al., 2000). BNC1 and BNC2 only have
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43.4% identity between their sequences, yet, BNC1 and BNC2 have a similar structure
with three separated pairs of two cysteine and two histidine (C2H2) ZFs and a nuclear
localization signal (NLS) between the first and second pair of ZFs (Romano et al., 2004;
Vanhoutteghem et al., 2011; Vanhoutteghem and Djian, 2004). ZF 1,2 has the most
similarity between BNC1 and BNC2 (92.1%) and has the most conservation across
species while ZF 3,4 and ZF 5,6 have less similarity between the two genes (Romano et
al., 2004; Vanhoutteghem et al., 2011). A highly conserved region between the two
proteins also lies in the N-terminus, yet the region has no obvious functional domain
(Vanhoutteghem et al., 2011; Vanhoutteghem and Djian, 2004). BNC2 has 6 exons, 5
introns and spans over 300 kb while BNC1 has 5 exons and spans over 29 kb (Romano
et al., 2004). Yet both genes are split up almost identically (Romano et al., 2004). Both
genes have a GC rich TATA-less promoter (Vanhoutteghem et al., 2011;
Vanhoutteghem and Djian, 2004) and therefore may have similar transcription
regulation. Mammals, birds, and fish express both genes (Lang et al., 2009; Romano et
al., 2004; Vanhoutteghem and Djian, 2004). Additional orthologs with a similar structure
to the Basonuclins includes the disco genes in Drosophila and other insects (Romano et
al., 2004). A single Basonuclin expresses in invertebrate chordates Branchiostoma
floridae and Ciona intestinalis which resembles BNC2 (Vanhoutteghem et al., 2011).
Therefore a duplication to create two Basonuclins occurred in a vertebrate ancestor and
BNC2 is the more ancient gene and most likely more important (Vanhoutteghem et al.,
2011). BNC2 is extremely conserved and more so than BNC1 with a sequence identity
of 97.2% between human and mouse (Vanhoutteghem and Djian, 2004). Out of fifty
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C2H2 ZF proteins, BNC2 is the ninth most conserved protein further indicating an
essential function for BNC2 (Vanhoutteghem and Djian, 2006).

Expression of BNC2
In the mouse, bnc2 expresses highly in the skin tissue, ovary, and kidney with
low levels in the testes, small intestine, and lung (Romano et al., 2004). No expression
was seen in the peripheral blood leukocytes, brain, colon, liver, spleen or thymus
(Romano et al., 2004; Vanhoutteghem and Djian, 2004). Closer inspection of
expression in mice revealed expression in the mesenchymal cells, mainly connective
tissue surrounding specific organs including the brain meninges, the cartilage, and the
bone as well as the male germ cells (Vanhoutteghem et al., 2011; Vanhoutteghem et
al., 2009; Vanhoutteghem et al., 2014). It is not expressed in the female germ cells
(Vanhoutteghem et al., 2014). In zebrafish, bnc2 expresses in the hypodermis, somatic
cells of ovaries, brain, dorsal spinal cord, eye, superficial cells of vertebrae, fins, gut,
kidney, and testes (Lang et al., 2009). Drosophila and insect disco proteins have similar
expression to BNC2 (Vanhoutteghem et al., 2009).
Interestingly transcription of the human BNC2 gene can be initiated at 6 different
exons with the canonical form being the most abundant (Vanhoutteghem and Djian,
2007). The human BNC2 gene also has alternative splice sites in the downstream
exons adding up to a total of 23 different exons (Vanhoutteghem and Djian, 2007).
There is potential for alternative transcripts in mice but not nearly as many in humans
indicating that the non-conserved transcripts play less of an important role
(Vanhoutteghem and Djian, 2007). There also seems to be tissue specific splicing since
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reverse-transcriptase PCR revealed different isoforms among human testes, kidney,
and keratinocytes (Vanhoutteghem and Djian, 2007). As mentioned in the previous
paragraph, BNC2 is expressed in several different cell types and therefore may have
many different transcripts among different cells. The Vanhoutteghem, et. al, 2007 study
states in the title that “The human basonuclin 2 gene has the potential to generate
nearly 90,000 mRNA isoforms encoding over 2,000 different protiens” (Vanhoutteghem
and Djian, 2007), a most astonishing amount. All identified transcripts in the
Vanhoutteghem, el. al, 2007 study were transfected into HeLa cells and only four
actually expressed (Vanhoutteghem and Djian, 2007). These four included the
canonical form, one with a modified fourth finger (adds more residues between the
second cysteine and first histidine), one that lacked ZF 5,6 and one that lacked all the
ZFs and nuclear localization signal (Vanhoutteghem and Djian, 2007). Northern blot
analysis in mouse shows the prescence of 9, 6, 4, and 2 kb transcripts (Romano et al.,
2004). The isoforms appearing in both mouse and human suggests that these four
isoforms may all play an important role in the tissues in which they are expressed.

Function of BNC2
As mentioned previously, BNC1, a nuclear ZF protein and TF, binds to and
activates transcription of ribosomal RNA promoters while also localizing to areas typical
of RNA polymerase I TFs (Iuchi and Green, 1999; Tian et al., 2001; Tseng et al., 1999).
Romano et al., 2004 tested the ability of BNC2 ZFs to bind to the ribosomal RNA
promoter in in vitro DNA binding assays and indeed BNC2 binds to the ribosomal RNA
promoter (Romano et al., 2004). Unlike BNC1, BNC2 does not shuttle out of the nucleus
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(Vanhoutteghem and Djian, 2006). BNC1 has a serine in the NLS that becomes
phosphorylated in order to transport into the cytoplasm (Vanhoutteghem et al., 2011;
Vanhoutteghem and Djian, 2006). BNC2 has a proline at this residue and therefore
cannot be phosphorylated (Vanhoutteghem et al., 2011; Vanhoutteghem and Djian,
2006). Interestingly, BNC2 was first seen as a 145 kDa protein to come down in the
insoluble fraction of the nuclear extract indicative of localizing to nuclear speckles
(Vanhoutteghem and Djian, 2006). Proteins involved in splicing, mRNA export,
nonsense mediated decay and polyadenylation (Fu and Maniatis, 1990; Kataoka et al.,
2000; Krause et al., 1994; Lamond and Spector, 2003; Zhou et al., 2000) also localize
to nuclear speckles potentially revealing a function for BNC2. Vanhoutteghem et al. also
saw that BNC2 co-localized with SC35, a splicing factor (Vanhoutteghem and Djian,
2006). Interestingly, the Phillipe Djian group also identified a larger isoform (160 kDa) of
BNC2 that comes down in the soluble fraction of the nuclear extract and appears in the
chromatin fraction indicative of BNC2 acting as a typical TF (Vanhoutteghem et al.,
2011; Vanhoutteghem et al., 2014). This isoform is actually the most abundant and
canonical isoform in mice (Vanhoutteghem et al., 2014). The isoform that locates to
nuclear speckles does not appear in mice (Vanhoutteghem et al., 2014).
Animal models with disruption of bnc2 gave intriguing phenotypes. Zebrafish with
truncating mutations of bnc2 lack body stripes, are significantly smaller than wild type,
and females are infertile (Lang et al., 2009). The dysmorphic ovaries in zebrafish
provide the first link between ovarian development and bnc2. The Lang et al. paper
noted that the oocytes from the mutants were fertilizable and that the infertility most
likely stems from the excess somatic ovarian tissue (Lang et al., 2009). This group also
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discovered that bnc2 acts non cell autonomously on the zebrafish stripes (the iridescent
iridiphores, the orange/yellow xanthaphores, and the black melanophores) (Lang et al.,
2009). Bnc2 is not expressed in the pigmented cells but resides in the hypodermis
(Lang et al., 2009). Bnc2 mutant mice are also dwarfed in size compared to wild-type
and infertile like the zebrafish mutants (Vanhoutteghem et al., 2011; Vanhoutteghem et
al., 2014). Interestingly, bnc2 mutant mice die neonatally due to cleft palate and other
craniofacial and tongue abnormalities (Vanhoutteghem et al., 2011; Vanhoutteghem et
al., 2009). Bnc2 is strongly expressed in the craniofacial sites affected; therefore bnc2
has a direct effect on the affected cells (Vanhoutteghem et al., 2009) unlike the indirect
effect on the pigmented cells of zebrafish. Vanhoutteghem et al. also discovered that
the craniofacial abnormalities were due to less cells entering mitosis during
development (Vanhoutteghem et al., 2009). Due to the expression in male germ cells,
Vanhoutteghem et al. investigated its role in spermatogenesis and discovered that bnc2
expression regulates mitosis of prospermatagonia and prevents meiosis in fetal testis
(Vanhoutteghem et al., 2014). Male germ cells undergo meiosis after birth while female
germ cells undergo meiosis in the fetus therefore could explain why bnc2 is expressed
in male but not female germ cells (Vanhoutteghem et al., 2014).
The 9p22.2 locus containing the BNC2 gene has also been identified as a human
height and skin pigmentation GWAS locus (Eriksson et al., 2010; Hider et al., 2013;
Jacobs et al., 2013; Visser et al., 2014; Wood et al., 2014). These studies implicate
BNC2 as the target gene of this locus since traits affected by BNC2 mutation or knock
out in animal models affect overlapping traits associated with 9p22 in human GWAS.
Further understanding of how this gene functions may reveal how changes in the
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transcription rates of BNC2 lead to ovarian cancer predisposition and development.
Here we characterize BNC2 as a TF and found that this protein acts primarily by binding
a specific DNA sequence located in enhancer regions proximal to genes involved in
cell-cell communication and chromatin remodeling. This work reveals a complex
regulatory network in a cancer risk locus and provides new insights into the etiology of
EOC.

Results

C2H2 Zinc Finger Proteins
The most obvious indicator of function for BNC2 is the presence of three
separated pairs of C2H2 ZF domains (Romano et al., 2004; Vanhoutteghem and Djian,
2004). A thorough understanding of how these domains work will give clues for the role
of BNC2 in ovarian cancer susceptibility. These domains contain two cysteine and two
histidine residues that, together, bind to zinc stabilizing a fold which creates two beta
sheets and an alpha helix (Wolfe et al., 2000). ZF domain containing proteins comprise
half of all known human and mouse TFs (Emerson and Thomas, 2009; Fulton et al.,
2009; Messina et al., 2004; Tupler et al., 2001) and are the largest protein family in
mammalian genomes (Ravasi et al., 2003). Approximately 700 human C2H2 ZF
proteins have been identified (Najafabadi et al., 2015; Vaquerizas et al., 2009; Weirauch
and Hughes, 2011).
C2H2 ZFs domains display sequence specific DNA binding through amino acids
at positions -1, 2, 3, and 6 of the ZF alpha helix with each DNA binding amino acid
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binding to one nucleotide (Elrod-Erickson et al., 1996; Klug, 2010; Lam et al., 2011;
Pavletich and Pabo, 1991; Wolfe et al., 2000). DNA binding usually requires two or
more ZF domains in tandem and these tandem ZF domains overlap binding with the
previous ZF binding site at the fourth base pair (Elrod-Erickson et al., 1996; Pavletich
and Pabo, 1991; Wolfe et al., 2000). The position 6 amino acid binds to the first
nucleotide on the primary strand (which could also be the fourth nucleotide bound to a
ZF in tandem), position 3 binds to the second, and -1 to the third. The position 2 amino
acid binds to the fourth nucleotide on the complementary strand (Wolfe et al., 2000).
Due to the unique way these ZF domains bind to DNA, many groups have
attempted to identify a “recognition code” for ZF domains and possibly design ZFs for
gene therapy, yet specificity has not been optimal (Corbi et al., 1998; Corbi et al., 1997;
Wolfe et al., 2000). Difficulty obtaining the “recognition code” most likely stems from
adjacent ZFs overlapping with the DNA sequence they recognize altering the individual
ZFs ability to bind to the predicted sequence (Isalan et al., 1997). Also, interactions
between amino acids of neighboring ZFs and within individual ZFs (outside of amino
acids at positions -1, 2, 3, and 6) can orient the protein in a way that alters the
sequence it should typically recognize (Wolfe et al., 2001). The specificity of these
proteins has been questioned but Lam et al. clearly explained that C2H2 ZFs in tandem
bind to degenerate motifs, in other words, they bind to many different but similar motifs
(Lam et al., 2011).
Najafabadi et al. developed an improved recognition code by testing 47,072
natural ZF domains sampled from all eukaryotes in tandem against a library of possible
nucleotide binding sequences using a bacterial one hybrid system (Najafabadi et al.,
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2015). This data was used to create a model that takes into account the degeneracy of
the binding (Najafabadi et al., 2015). Many bacterial one hybrid sequences and
predicted sequences were confirmed via ChIP-seq and protein binding microarray
(PBM) (Najafabadi et al., 2015). A PBM is an array with double stranded DNA probes
representing all possible 8mer sequences DNA binding proteins can recognize (Berger
and Bulyk, 2009; Berger et al., 2006). Glutathione-S-transferase (GST)-tagged DNA
binding proteins are applied to the array followed by a fluorophore for GST to asses
which sequences the protein recognizes (Berger and Bulyk, 2009; Berger et al., 2006).
It has been shown that C2H2 ZF domains can also bind RNA or proteins, but
Najafabadi et al. clearly demonstrates that the majority bind DNA (Najafabadi et al.,
2015). Again, due to the unique nature in which ZF domains recognize and bind to
nucleotide motifs, these TFs have the most unique binding sites compared to any other
TFs (Najafabadi et al., 2015).

BNC2 Zinc Fingers Recognize Specific DNA Sequences in vitro
BNC2 contains three pairs of C2H2 ZFs suggesting that it interacts with specific
DNA

sequences and

plays

a

role

in transcription regulation

(Figure 15A)

(Vanhoutteghem and Djian, 2004, 2006). In order to identify potential DNA sequences
recognized by the BNC2 ZFs, bacterially expressed GST-tagged constructs of each ZF
pair (Figure 14A) were applied to a protein binding microarray (PBM) of overlapping,
rationally randomized nucleotides (Berger and Bulyk, 2009; Berger et al., 2006; Lam et
al., 2011). The top ten scoring sequences for each of the individual ZF pairs were then
aligned to generate a logo using position weight matrix scoring (Figure 15A). The motifs
65

Figure 14: BNC2 binds to its own promoter. A. Coomassie stain of protein
purification of GST tagged BNC2 ZF pairs: 1,2; 3,4; and 5,6. B. CPB tagged GFP and
BNC2 were over expressed in 293FT cells. Lysates of these cells were
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immunoprecipitated with either Rabbit IgG or the Prestige antibody for BNC2 (Sigma).
Immunoprecipitates undergo Western Blot for CBP. A band for BNC2 between the 150
kDA and 250 kDA mark appears in the input and BNC2 IP for over expressed BNC2 but
not in the input and BNC2 IP for over expressed GFP nor in the IgG IP. C. ChIP
indicates that BNC2 binds to its own promoter. Potential ZF 5,6 binding sites within the
BNC2 promoter are indicated with black lines. Black boxes indicate location of
amplicons analyzed with ChIP qPCR. In iOSE11 and iFTSEC283 cells there is a signal
that BNC2 is indeed binding to those sites (bar graph). Raw ChIP-seq data for BNC2 in
iOSE11 cells replicate the binding at the -914 position (blue bar).

for ZF1,2 and 5,6 are almost identical to the predicted C2H2 “recognition code”
(Najafabadi et al., 2015). The data for ZF3,4 yielded lower-confidence data and did not
match the recognition code predictions (Figure 15A) (Berger et al., 2006). The 3’ end of
the ZF1,2 and ZF5,6 binding motifs contain the same nucleotides at the same position
and weight, consistent with the similarity between ZF2 and ZF6 in amino acid residues
at positions that specifically interact with DNA (Figure 15A). Interestingly, the BNC2
promoter contains two of the top 10 BNC2 ZF5,6 PBM binding sequences (Figure 14C).
To validate BNC2 binding sequences identified using the PBM we conducted
ChIP in iOSE11 and iFTSEC283 cells for endogenous BNC2 (Figure 14B) to determine
its presence at the putative PBM sites (-582 and -914 base pair (bp) upstream of the
TSS) found at the BNC2 locus as well as at site >300 bp (-2184) from the TSS as a
negative control. A significantly larger amount of DNA pulled down with the BNC2
antibody than with the IgG control at the -582 (iOSE11 p = 2.6 x 10-3, iFTSEC283 p =
8.3 x 10-3) and -914 (iOSE11 p = 1.8 x 10-4, iFTSEC283 p = 2.0 x 10-6) bp sites, but not
at the -2184 bp site (Figure 14C). This supports that BNC2 recognizes the sites
identified in the PBM experiment and also suggests an auto-regulatory mechanism.
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BNC2 Genome-wide Target Sites
To determine the sites in the genome bound by BNC2 in ovarian cells we
conducted ChIP-seq in iOSE11 and iFTSEC283 cells. MEME, a motif analysis tool,
identified a motif centrally enriched in the ChIP-seq peaks for both cell types (Figure
15B). ChIP-seq data replicated BNC2 binding in the iOSE11 cells at the -914 position
tested in ChIP-qPCR (Figure 14C). Interestingly the motif identified by MEME seems to
be a concatenation of the motif for ZF1,2 and the reverse complement motif for ZF5,6
(Figure 15B). ZF1,2 and 5,6 are greater than 500 amino acids away from each other
potentially allowing the protein to fold in a way that allows the two ZF paired domains to
bind to the DNA as dimers (Figure 15B). The originally identified sequence has a 75%
homology to the MEME motif (Figure 15B). About 50% and 25% of the iFTSEC283 and
iOSE11 peaks, respectively, have the motif near the peak summits (Figure 15C).
We annotated the transcriptional landscape of the BNC2 ChIP-seq peaks in
iOSE11 cells by overlapping them with ChIP-seq for H3K27ac and H3K4me1 in iOSE11
cells and at core promoters (1 kb of TSS) (Figure 15D). BNC2 ChIP-seq peaks that
overlap with H3K4me1 and H3K27ac were considered regions of active enhancers.
Peaks that only overlap with H3K27ac were considered active chromatin. Peaks that
only overlap with H3K4me1 were considered poised enhancers. Sixty-six percent of
BNC2 ChIP-seq peaks overlap with a regulatory element. Interestingly, a small
percentage of BNC2 recognition sites reside in core promoters indicating BNC2 works,
in part, by modulating the activity of enhancers.
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Figure 15. BNC2 recognizes specific nucleotide sequence. A. BNC2 is
characterized as a C2H2 ZF protein with three pairs of ZFs (called 1,2; 3,4; 5,6). BNC2
ZF binding sites were identified in vitro by applying recombinant proteins of each ZF pair
69

to a PBM. Position weight matrices of all potential binding sites with significant scores
for each BNC2 ZF pair are shown as logos. Motifs predicted based on the protein
sequence of the ZF domains aligned with ZF1,2 and ZF5,6. The 3’ end of the
sequences recognized by ZF1,2 and ZF5,6 reveal the same nucleotides. Inspection of
the amino acid sequences for ZF2 and ZF6 show that amino acid residues at position
-1, 2, 3, and 6 within the alpha helix that specifically interact with DNA nucleotides (in
red) are the same. B. The ChIP-Seq motif identified by MEME seems to be a
concatenation of the predicted motif for ZF1,2 and the predicted reverse complement
motif for ZF 5,6 or vise-a-versa. C. Enrichment of motif relative to ChIP-Seq peak
summits. D. A Circos table depicts the percentage of BNC2 ChIP-seq sites overlapping
with chromatin mark’s ChIP-seq sites in iOSE11 cells. Sites containing only H3K4me1
marks are considered poised enhancers. Sites containing H3K4me1 and H3K27ac
marks are considered active enhancers. Sites containing only H3K27ac marks are
considered active chromatin. Sites within 1 kb of a TSS that contain H3K27ac marks are
considered active promoters. Sites within 1 kb of a TSS without histone marks are
considered poised promoters.

Identification and Validation of BNC2 Target Genes
To identify target genes regulated by enhancers containing BNC2 binding sites
we used the Galaxy Cistrome program (Liu et al., 2011). This generated a list of 445
genes in iOSE11 cells and 725 genes in iFTSEC283 cells with TSS within 30 kb of the
BNC2 ChIP-seq peak centers. One hundred and sixty eight genes lie near BNC2 ChIPseq peaks in both cell types. KEGG Pathway analysis identified several pathways that
are likely targets including chemokine and TGF-beta signaling pathways (Figure 16).
Next, we selected a set of 89 genes implicated in ovarian cancer, ovarian cancer
GWAS, follicular development, ovarian development (Bojesen et al., 2013; Cancer
Genome Atlas Research, 2011; Goode et al., 2010; Nef et al., 2005; Permuth-Wey et
al., 2013; Pharoah et al., 2013; Ramakrishna et al., 2010; Schindler et al., 2010; Shen
et al., 2013; Song et al., 2009), were part of the significant KEGG pathways, or
contained ChIP-seq peaks within their core promoter (within 1kb from the TSS)(Table 3)
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Figure 16: Kegg Pathway analysis of downstream targets of BNC2. A Kegg
Pathway analysis on all genes within 30 kb of BNC2 ChIP-seq sites in iOSE11 and
iFTE283 cells revealed several pathways reaching significance. Bar graphs in red
indicate the pathways relevant to cancer. Genes within 30 kb of BNC2 ChIP-seq sites
and within those pathways were analyzed further.

and tested whether overexpression of BNC2 in HEK 293T (Figure 17) would modulate
their expression measured by Nanostring. Several genes implicated in ovarian cancer
and ovarian development or that mapped to KEGG Focal Adhesion, ECM-receptor
interaction or TGF-β Signaling Pathways showed changes in expression induced by
BNC2 overexpression as measured 24h after transfection (Table 4).
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Figure 17. Overexpression of BNC2 in HEK293FT cells. Western blot indicates the
over-expression of CBP-tagged BNC2 in 293FT cells. Blotting for the CBP tag and the
antibody for BNC2 clearly show that BNC2 is over-expressed.

Table 3: Expression analysis of downstream target genes of BNC2
Gene

Cell Line

Pathway

P-Value

FAM49B

FTE

Ovarian Cancer

0.00015

ITGB5

FTE

ECM-receptor interaction, Focal Adhesion

0.00046

PKDCC

FTE

Ovarian Development

0.00066

CCND3

FTE

Focal adhesion, WNT Signaling Pathway, JAK-STAT Signaling Pathway

0.00107

CEP55

FTE

Ovarian Development

0.00264

GUSB

Reference

0.00528

JUN

FTE,
OSE

Focal adhesion, WNT Signaling Pathway, MAPK Signaling Pathway

0.00627

COL6A3

FTE

ECM-receptor interaction, Focal Adhesion

0.00698

ITGA3

OSE

Focal Adhesion

0.00711

CAPN2

FTE

Focal adhesion

0.00943

SLFN12

FTE

Promoter with Peak

0.01012

FBXO15

OSE

Promoter with Peak

0.01375
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Table 3 (Continued)
Gene

Cell Line

Pathway

P-Value

COL4A5

FTE

ECM-receptor interaction, Focal Adhesion

0.01748

FEM1A

OSE

Promoter with Peak

0.02064

Reference

0.02961

TGF-beta Signaling Pathway

0.03906

Reference

0.0451

TGF-beta Signaling Pathway

0.05324

Reference

0.05469

TTI2
TGFBR3

FTE

STK35
BMP6

FTE

SMG5
SNAI2

FTE

Adherens Junction

0.06178

PPP3CA

FTE

WNT Signaling Pathway, MAPK Signaling Pathway

0.06363

FN1

FTE

ECM-receptor interaction, Focal Adhesion

0.06388

FASLG

FTE

MAPK Signaling Pathway

0.07104

RANBP10

OSE

Promoter with Peak

0.07547

BANP

OSE

Promoter with Peak

0.0801

Reference

0.0833

FTE, OSE

Ovarian Development

0.08539

Reference

0.09168

MAP3K8

FTE

MAPK Signaling Pathway

0.09761

ID1

OSE

TGF-beta Signaling Pathway

0.10798

LSM5

FTE

Follicular Development

0.10818

ACTG1

OSE

Focal Adhesion, Adherens Junction

0.114

GBA

OSE

Promoter with Peak

0.1165

PPP6R3

OSE

Promoter with Peak

0.11658

POLDIP3

OSE

Promoter with Peak

0.11742

INO80
SH2D4A
TOX4

CD59

FTE

Promoter with Peak

0.12042

ANK3

FTE

Ovarian Development

0.13177

THOC6

Ose

Promoter with Peak

0.13242

LEP

FTE

JAK-STAT Signaling Pathway

0.14078

HNF1B

FTE

GWAS

0.14732

LMO7

FTE

Adherens Junction

0.1582

DKK1

FTE

WNT Signaling Pathway

0.16114

Reference

0.17339

ACTB
MYLK

FTE

Focal adhesion

0.17567

LEPR

FTE

JAK-STAT Signaling Pathway

0.17834

ACTN4

OSE

Focal Adhesion, Adherens Junction

0.21508

KBTBD6

OSE

Promoter with Peak

0.21679

FSCN1

OSE

Promoter with Peak

0.23926

BTBD19

OSE

Promoter with Peak

0.25273

LAMB1

FTE

ECM-receptor interaction, Focal Adhesion

0.25369

TCTEX1D4

OSE

Promoter with Peak

0.26229

THBS1

FTE, OSE

ECM-receptor interaction, Focal Adhesion, TGF-beta Signaling Pathway

0.27286
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Table 3 (Continued)
Gene

Cell Line

Pathway

P-Value

CD36

FTE

ECM-receptor interaction

0.27883

Reference

0.29711

Ovarian Development

0.30676

EIF2C1
SPHK1

OSE

ITGA5

OSE

Focal Adhesion

0.31715

RASGRP1

FTE

MAPK Signaling Pathway

0.33703

FAP

FTE

Ovarian Cancer

0.33708

RASGRP3

FTE, OSE

MAPK Signaling Pathway

0.34904

RASGRF2

OSE

MAPK Signaling Pathway

0.35168

WASL

FTE, OSE

Adherens Junction

0.35776

DUSP1

OSE

MAPK Signaling Pathway

0.36196

PDCD1LG2

FTE

Promoter with Peak

0.37688

CCDC80

FTE

Promoter with Peak

0.39362

Reference

0.39529

PRDM4
SMAD3

FTE, OSE

Adherens Junction, TGF-beta Signaling Pathway, WNT Signaling
Pathway

0.39745

CTGF

FTE, OSE

Follicular Development

0.40642

TRIB2

FTE

Ovarian Development

0.43142

SPARC

FTE

Follicular Development

0.44907

PDGFC

FTE

Focal adhesion

0.47425

CLPB

OSE

Promoter with Peak

0.49331

COL4A6

FTE

ECM-receptor interaction, Focal Adhesion

0.49815

CACNG6

OSE

MAPK Signaling Pathway

0.51917

UHRF1BP1L

FTE

Ovarian Development

0.54734

LTBP1

FTE

TGF-beta Signaling Pathway

0.56817

IL22

FTE

JAK-STAT Signaling Pathway

0.57974

IFNGR1

FTE

JAK-STAT Signaling Pathway

0.58208

IL22RA2

FTE, OSE

JAK-STAT Signaling Pathway

0.58664

CD44

FTE

Ovarian Development, ECM-receptor interaction

0.5942

RAI14

FTE

Promoter with Peak

0.63357

DUSP3

FTE

MAPK Signaling Pathway

0.64444

PRKCA

FTE

Focal adhesion, WNT Signaling Pathway, MAPK Signaling Pathway

0.66141

RPS6KA2

FTE

MAPK Signaling Pathway

0.6638

DUSP10

FTE, OSE

MAPK Signaling Pathway

0.67452

GNA12

OSE

MAPK Signaling Pathway

0.70082

TSNAXIP1

OSE

Promoter with Peak

0.71591

BCL2L1

FTE

JAK-STAT Signaling Pathway

0.73164

AP2S1

OSE

Promoter with Peak

0.74506

TGFBR2

FTE

Adherens Junction, TGF-beta Signaling Pathway, MAPK Signaling
Pathway

0.76959

ITGB2

OSE

promoter with Peak

0.83732

SMAD7

FTE, OSE

TGF-beta Signaling Pathway, Promoter with Peak

0.85264

PLOD2

FTE

Ovarian Development

0.85924
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Table 3 (Continued)
Gene

Cell Line

GIGYF2

Pathway

P-Value

Reference

0.8774

GADD45B

OSE

MAPK Signaling Pathway

0.89367

ZBTB4

OSE

Promoter with Peak

0.89726

PHF12

OSE

Promoter with Peak

0.89743

SEMA3C

OSE

Ovarian Development

0.90991

BNC2 Interacts with the NuRD Complex
To further elucidate the function of BNC2 in transcription regulation we used tandem
affinity purification to isolate proteins that are in complex with ectopically expressed
tagged BNC2 in HEK293T cells (Figure 18A). Gene ontology enrichment analysis using
the web gestalt program (http://bioinfo.vanderbilt.edu/webgestalt/) (Zhang et al., 2005)
indicates that BNC2 interacts with proteins enriched in the NuRD complex of
transcription repression (p = 2.75 x 10-11) (Figure 18B, red circle), RNA binding proteins
(p = 9.47 x 10-6), and proteins involved in gene expression (p = 2.78 x 10-6).
Immunoprecipitation of endogenous MTA2, a component of the NuRD complex,
followed by a western blot for endogenous BNC2 was used to verify the interaction
(Figure 18C).
Since BNC2 interacts with the NuRD complex we then tested the extent to which
BNC2 constructs fused to GAL-4 DNA binding domain represses transcription of a
heterologous promoter (Figure 18D). Full length and fragments of BNC2 significantly
repressed expression of luciferase compared to GAL-4 alone indicating that BNC2
displays transcription repression activity and may interact with the NuRD complex via
multiple regions (Figure 18E).
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Table 4: Genes with significant expression changes upon differential expression
of BNC2.
iFTE283

P-Value

Expression
Correlation
to BNC2

Pathway

21553

0.00014782

-

Ovarian
Cancer

PKDCC

16237

0.00066222

-

Ovarian
Development

COL4A5

24983

0.0174824

-

CAPN2

5635|-5189

0.00942743

-

ITGB5

8074

0.00046358

-

COL6A3

-17808

0.00698256

+

JUN

20445

0.00626649

+

TGFBR3

5215|-14508

0.0390608

+

CCND3

-25565

0.00106617

+

SLFN12

-819

0.0101215

+

CEP55

-24627|24647

0.002645

+

Ovarian
Development

Gene

TSS to Peak
Center

P-Value

Expression
Correlation
to BNC2

Pathway

JUN

-20156

0.00626649

+

ITGA3

-4619

0.00711417

+

FBXO15

-620|-721

0.01375

+

FEM1A

-65

0.0206431

-

Gene

TSS to Peak
Center

FAM49B

Focal
Adhesion
Focal
adhesion
Focal
Adhesion
Focal
Adhesion
Focal
adhesion
TGF-beta
Signaling
Pathway
Focal
adhesion
Promoter with
Peak

iOSE11
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Focal
adhesion
Focal
Adhesion
Promoter with
Peak
Promoter with
Peak

Figure 18: BNC2 interacts with the NuRD complex. A. TAP-tagged control GFP and
BNC2 purified protein complexes from HEK293FT cells. B. Gray nodes represent
proteins found in complex with BNC2. Blue and orange edges indicate interactions
identified by tandem affinity purification coupled to mass-spectrometry or present in
published datasets identified by the Cytoscape plugin BisoGenet, respectively. Notably,
BNC2 interacts with proteins that are part of the NuRD complex (red circle). C.
Confirmation immunoprecipitation indicates endogenous BNC2 interacts with NuRD
protein MTA2. D. BNC2 constructs (gray boxes) fused to the GAL4 DNA binding domain
(DBD) (orange boxes) were co-transfected with the GAL4-TK-Luc reporter vector. E.
Illustration of the GAL4-tk-Luc construct (top). Measurements of relative luciferase
levels determine which constructs have repression activity compared to the GAL4-DBD
alone (bottom).

Summary
Here we have shown that BNC2 does indeed act as a TF. It recognizes a specific
DNA binding motif in vitro which also appears as the predicted motif based on previous
TF binding data. The motifs for ZF1,2 and ZF 5,6 also appear in the MEME analysis as
a concatenation indicating that BNC2 binds to DNA in a folded form. BNC2 binding also
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overlaps with previously identified regulatory regions, more specifically enhancers, in
ovarian cells. Changes in BNC2 expression also lead to changes in downstream target
gene expression. Interestingly many affected genes regulate cell-cell communication. A
previous study suggests that BNC2 acts non-cell autonomously in the development of
the Xanthaphores (stripes) in Zebrafish. Therefore, BNC2 may play a similar role in
ovarian development. BNC2 also interacts with other TFs. Most interestingly, BNC2
interacts with the NuRD complex, a complex involved in chromatin remodeling and
histone deacetylation. In general the NuRD complex acts as a repressor of transcription
and a reporter assay with BNC2 constructs suggests that BNC2 represses transcription
in this context.

Materials and Methods

Protein Binding Microarray
Fragments containing cDNAs of the each ZF pairs were PCR amplified from a
plasmid containing full length BNC2 cDNA (gift from Dr. Philippe Djian). Primers
containing Gateway recombination sites are described in Table 5. PCR products were
cloned into pDONR221 using the BP recombination kit and transferred to pDEST15 as
a fusion to GST using LR recombination kit (Invitrogen). After plasmid purification,
pDONR221 plus ZF plasmids undergo into using the LR recombination kit from
Invitrogen. Plasmids containing GST-tagged ZFs were expressed in BL21 E. coli and
purified using GT sepharose beads. Purified GST-ZFs were eluted from beads with 50
mM reduced glutathione (Figure 14A). The eluate was then dialyzed in TBS with 50 µM
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Zinc Acetate and proteins were quantified using Bio-Rad Protein Assay. For the Protein
Binding Microarray, 0.5 µg of each GST-ZF protein construct were applied individually
to two differently designed arrays designated ME and HK as previously described
(Berger and Bulyk, 2009; Lam et al., 2011). ZFs typically bind to degenerate motifs and
have the potential to have more than one recognition sequence (Lam et al., 2011;
Ramirez et al., 2008). Each DNA probe sequence is given an E-score which is similar to
the Area under the ROC curve statistical metric and an E-score above 0.45 was
considered significant (Berger et al., 2008).

ChIP/ChIP-Seq for BNC2
ChIP was performed as previously described (Gomes et al., 2006) using a
validated BNC2 antibody (Sigma Atlas) (Figure 14B). In brief, iOSE11 or iFTSEC283
cells grown to 70% confluence in media with a 1:1 ratio of MCDB105/Medium 199, 15%
Fetal Bovine Serum (FBS), 10 ng/mL Epidermal Growth Factor, 0.5 µg/mL
hydrocortisone, 5 µg/mL insulin, and 34 µg/mL Bovine Pituitary Extract were crosslinked with 1% Formaldehyde in PBS. Crosslinking is quenched by adding Glycine to a
concentration of .125M. After washing, cells are collected in Szaks’ RIPA buffer (150
mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris HCl pH8, 5 mM
EDTA, Protease Inhibitors, 50 mM NaF, 0.2 mM sodium orthovanadate, 0.5 mM PMSF)
and the lysate is brought to approximately 1 mg/mL. The lysate is then sonicated in
Biogenode Sonicating Water Bath for 12 cycles of 30 seconds on and 30 seconds off for
8 minutes. One mg of protein is then mixed with 40 µL of 50% slurry protein A/G
agarose beads (Santa Cruz) previously washed in Szaks’ RIPA buffer and pre-cleared
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for 1-2 hours at 4°C. Pre-cleared lysate is then mixed with 5 µg of BNC2 antibody
(Sigma Atlas) and 40 µL of 50% slurry protein A/G agarose beads previously washed in
Szaks’ RIPA buffer and saturated with 1 mg/mL BSA. The mix was incubated overnight
at 4°C while rotating. Beads are then washed twice with Szaks’ RIPA Buffer, four times
with Szaks’ IP wash buffer (100 mM Tris HCl pH 8.5, 500 mM LiCl, 1% NP-40, 1%
deoxycholate), twice again with Szak’ RIPA Buffer and twice with cold TE.
Immunocomplexes are eluted by incubating samples at 65°C for 10 minutes in 1.5X
Talianidis Elution Buffer (70 mM Tris HCl pH 8, 1 mM EDTA, 1.5% SDS). Crosslinks
were reversed by bringing samples to 200 mM NaCl solution and incubating at 65°C for
5 hours. DNA was purified by phenol-chloroform extraction and re-suspended in 50 µL
10 mM Tris pH 8.0.
Real time qPCR was performed using Sybr Green chemistry with primers at the 2184, -914, and -582 positions relative to the TSS (Table 5) in an Applied Biosystems
7900HT Fast Real Time PCR System using absolute quantification with genomic DNA
as a standard control to measure the amount of DNA bound by BNC2 in comparison to
the IgG control. Data were normalized by taking the percentage of DNA for each site of
the highest bound site. ChIP for each cell line was performed in four biological
replicates.
For BNC2 ChIP-Seq, four individual ChIP samples were pooled for each cell line
(iOSE11 and iFTSEC283) in two biological replicates. Immunoprecipitated DNA was
used to generate a sequencing library using the NuGEN Ovation Ultralow Library
System with indexed adapters (NuGEN, Inc., San Carlos, CA). The library was PCR
amplified and size-selected using AxyPrep Fragment Select beads (Corning Life
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Sciences – Axygen Inc., Union City, CA). The size and quality of the library was
evaluated using the Agilent BioAnalzyer, and the library was quantitated with the Kapa
Library Quantification Kit (Kapa Biosystems, Woburn MA). Each enriched DNA library
was then sequenced on an Illumina HiScan SQ sequencer to generate 20-30 million
100-bp-end reads. The raw sequence data was de-multiplexed using the Illumina
CASAVA 1.8.2 software (Illumina, Inc., San Diego, CA) and binding sites were identified
using the MACS software (Zhang et al., 2008) using input DNA as a control, and a band
with setting of 300. All other parameters were set to defaults. The .bam and .wig files
were visualized and inspected using the UCSC genome browser (Kent et al., 2002).
Peaks used for further analysis had an intensity greater than 0.05 (reads/length),
number of reads greater than 50, and a fold change compared to the input greater than
10.
To identify target genes, bed files were uploaded into Galaxy Cistrome (Liu et al.,
2011) and the peak2gene Peak Center Annotation tool was used on both the iOSE11
and iFTSEC283 BNC2 ChIP-Seq files to generate a list of genes within 30 kb of the
peak centers. BNC2 ChIP-seq peaks for each of the iOSE11 and iFTE283 samples
were ranked by their MACS p-values, and the top 2000 peaks with the most significant
p-values were selected for de novo motif discovery. The 500 bp sequences surrounding
the summits of the top 2000 peaks were extracted, and de novo motif discovery was
performed for iOSE11 and iFTE283 samples separately using MEME-ChIP (Machanick
and Bailey, 2011) with the following parameters: ZOOPS mode, minimum MEME width
6, maximum MEME width 30, maximum 5 MEME motifs, and DREME E-value cutoff
0.05. The top scoring MEME-ChIP motif for both samples were almost identical, and
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thus were averaged. Enrichment of this motif at the peak summits was examined using
CentriMo (Bailey and Machanick, 2012) for iOSE11 and iFTE283 samples separately,
as central enrichment is often associated with direct binding of the protein to DNA
(Bailey and Machanick, 2012).
DNA-binding preferences were predicted for each of the three ZF pairs of BNC2
(ZF1-2, ZF3-4, and ZF5-6) using B1H-RC (Najafabadi et al., 2015), which consists of a
set of Random Forest models that take the protein sequence as input and predict
nucleotide preferences at different DNA positions. These predictions were compared to
the PBM motifs obtained for the same ZF pairs, as well as to the de novo motif obtained
from full-length BNC2 ChIP-seq.

Nanostring
pNTAP-BNC2 (or the empty vector) was transfected with Fugene 6 into 293FT
cells grown to 70% confluence in DMEM and 10% FBS. Cells were harvested after 24
hours and BNC2 overexpression was confirmed by Western blotting (Figure 17). RNA
was isolated using Trizol RNA Isolation (Life Technoligies) and cleaned using Qiagen
RNeasy Mini Kit (Qiagen). The three biological replicates for 293FT cells with the empty
vector or over-expressed BNC2 were applied to a Nanostring platform containing
probes for 86 genes and controls (Table 3). A custom NanoString nCounter Gene
Expression (GX) CodeSet with probes representing 97 genes was developed and the
sample was processed on the NanoString nCounter Analysis System according to the
manufacturer’s protocol (NanoString Technologies, Seattle WA). The resulting .RCC
files containing raw counts were checked for quality in the NanoString nSolver Analysis
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Software v1.1, and then exported for normalization and analysis. TTI2, PRDM4, STK35,
TOX4, INO80, GIGYF2, and SMG5 were used as reference genes to normalize the data
in the NanoString nSolver Analysis Software v 1.1. These genes had a %CV < 50.
Normalized data is then analyzed using Graph Pad Prism 6. Genes were considered to
be differentially expressed had a p-value <.05 (two tailed t-test).

Tandem Affinity Purification coupled to LC-MS/MS
Full length BNC2 cDNA was amplified using primers containing BamHI and SalI
restriction enzyme sites (Table 5) and cloned into pNTAP-B vector cut with BamHI and
XhoI. Construct 1-236 was obtained by cutting the 1-524 PCR amplification product with
BamHI and XhoI (site at 710 bp). Log growing 293FT (1 x 108 cells) grown in DMEM
plus 10% FBS were transfected with 200 μg pNTAP-BNC2 construct using the calcium
phosphate method, as previously described (Swift et al., 2001). Purification of TAPtagged BNC2 complexes was performed using the InterPlay TAP purification kit
(Stratagene) (Woods et al., 2012). A TAP-GFP construct was used as a control to
reduce false positive interactions using this purification method.
Following in-gel tryptic digestion, peptides were extracted and concentrated
under vacuum centrifugation. A nanoflow liquid chromatograph (Easy-nLC, Proxeon,
Odense, Denmark) coupled to an electrospray ion trap mass spectrometer (LTQ,
Thermo, San Jose, CA) was used for tandem mass spectrometry peptide sequencing
experiments. The sample was first loaded onto a trap column (BioSphere C18
reversed-phase resin, 5µm, 120Å, 100 µm ID, NanoSeparations, Nieuwkoop,
Netherlands) and washed for 3 minutes at 8 mL / minute. The trapped peptides were
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eluted onto the analytical column, (BioSphere C18 reversed-phase resin, 150mm, 5µm,
120Å, 100 µm ID, NanoSeparations, Nieuwkoop, Netherlands). Peptides were eluted in
a 30 minute gradient from 5% B to 45% B (solvent A: 2% acetonitrile + 0.1% formic
acid; solvent B: 90% acetonitrile + 0.1% formic acid) with a flow rate of 300 nL/minute.
Five tandem mass spectra were collected in a data-dependent manner following each
survey scan. Sequences were assigned using Mascot (www.matrixscience.com)
searches against human Swiss Prot entries (Sprot_20090505, 20402 entries).
Carbamidomethylation of cysteine, methionine oxidation, and deamidation of
asparagine and glutamine were selected as variable modifications, and as many as 2
missed tryptic cleavages were allowed. Precursor mass tolerance is set to 2.5 and
fragment ion tolerance to 0.8. Results from Mascot were compiled in Scaffold, which
was used for manual inspection of peptide assignments and protein identifications.
Database searches were conducted against human entries in the SwissProt
database (v.20090505) using Mascot (Matrix Science, London, UK; version 2.2.04)
(Perkins et al., 1999), assuming the digestion enzyme trypsin and allowing as many as
2 missed cleavages. Tandem mass spectra were matched to peptide sequences with a
peptide ion mass tolerance of 1.2 Da and fragment ion mass tolerance of 0.80 Da.
Oxidation of methionine and carbamidomethylation of cysteine were specified as
variable modifications. Assignments were manually verified by inspection of the tandem
mass spectra and coalesced into Scaffold reports (v.2.0, available at
www.proteomesoftware.com) for statistical analysis and data presentation.
Scaffold (version Scaffold_2_04_00, Proteome Software Inc., Portland, OR) was
used to validate MS-MS based peptide and protein identifications. Peptide
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identifications were accepted if they could be established at greater than 95.0%
probability as specified by the Peptide Prophet algorithm (Keller et al., 2002). Protein
identifications were accepted if they could be established at greater than 50.0%
probability and contained at least 2 identified peptides. Protein probabilities were
assigned by the Protein Prophet algorithm (Nesvizhskii et al., 2003). Proteins that
contained similar peptides and could not be differentiated based on MS-MS analysis
alone were grouped to satisfy the principles of parsimony. Proteins appearing in control
GFP purification and in the BNC2 samples were removed from the final datasets. Final
protein list underwent gene ontology enrichment analysis from the WebGestalt program
using h_sapiens genome as a reference set (Zhang et al., 2005).

Transcriptional Repression Assay
Fragments as well as full length BNC2 were PCR amplified from plasmid
containing BNC2 cDNA using primers to clone in frame to GAL4 DBD (Table 5). These
plasmids were then co-transfected with pGAL4-TK-Luc (Yang et al., 2001) expressing
firefly luciferase and pRL-SV40 expressing Renilla luciferase as an internal control into
293FT cells. Luciferase levels were measured 24 hours post-transfection using Dual
Luciferase II Assay Kit (Promega).

Table 5: List of oligos used in this study:
Primer Name

Sequence

Assay

T5 FWD

attb-TAAGTAGAGACGGGGTTTCA

Tiling Clones

T5 REV

attb-CTGATGGACCATTCTTCACT

Tiling Clones

T6 FWD

attb-GGTGGAAAGCAAACTAAATG

Tiling Clones

T6 REV

attb-TAGTTCTGTTGTGCAGGTTG

Tiling Clones

T7.1 FWD

attb-TGGGGGTTTTCATTGCCAGG

Tiling Clones
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Table 5 (Continued)
Primer Name

Sequence

Assay

T7.1 REV

attb-GACTCGACGATGTGCTGTCC

Tiling Clones

T7.2 FWD

attb-GTGAAGCTGCACAGACACTA

Tiling Clones

T7.2 REV

attb-CAGAATGTTGCACAAAAAGA

Tiling Clones

T7.3 FWD

attb-TCTTTTTGTGCAACATTCTG

Tiling Clones

T7.3 REV

attb-ATTAAGTTGGGTGGTGTTTG

Tiling Clones

T7.4 FWD

attb-ACCGTGCTGAACCCTTAACT

Tiling Clones

T7.4 REV

attb-GAGCCCAGGACTGTGGTTAC

Tiling Clones

T7.5 FWD

attb-CTCTGCTTTTGTCTGCTTCT

Tiling Clones

T7.5 REV

attb-GGACCTACGGGAACTTTTAC

Tiling Clones

T7.6 FWD

attb-ATTCCGAATGTGAAGACAAG

Tiling Clones

T7.6 REV

attb-TTTTCACTAGGAACCGGTAA

Tiling Clones

T7.7 FWD

attb-GTGCAAGCCCCACAAGTTTT

Tiling Clones

T7.7 REV

attb-GATGCAACCTGTCCCCAGAA

Tiling Clones

T7.8 FWD

attb-TCTCCGAGTTATGCAGATTT

Tiling Clones

T7.8 REV

attb-GAGCTTTGCAAGTTAGAGGA

Tiling Clones

T8 FWD

attb-AGAGACAACCCAAGATAGCA

Tiling Clones

T8 REV

attb-CCAATGACGAAATGTATGTG

Tiling Clones

T11 FWD

attb-GGGTGGGGGTGAGGATGATA

Tiling Clones

T11 REV

attb-TTTGCCTGTAGTGGGTGCTC

Tiling Clones

T12 FWD

attb-TGCCTGGCTTAGTCTTTATT

Tiling Clones

T12 REV

attb-AGGAGAAGGAATAGCTGCTT

Tiling Clones

TC FWD

attb-GAATATGACTGGCACCACTT

Tiling Clones

TC REV

attb-AATAAAGACTAAGCCAGGCA

Tiling Clones

rs62541878 sense

tatctctacaaaatatatatatatatatatataaatttaccaggcatcgtggcttgc

rs62541878 antisense

gcaagccacgatgcctggtaaatttatatatatatatatatatattttgtagagata

rs62541920 sense

atacatacacagtgagtcatttaagagtttcacattctgccttc

rs62541920 antisense

gaaggcagaatgtgaaactcttaaatgactcactgtgtatgtat

rs12379183 sense

tcaaagagaaaatagagcaaaaagaacaaaactgatgttgttatgtacggatattt

rs12379183 antisense

aaatatccgtacataacaacatcagttttgttctttttgctctattttctctttga

rs10962647 sense

tcagctctgcttttgtctgctgctttttgtaatcacatatctc

rs10962647 antisense

gagatatgtgattacaaaaagcagcagacaaaagcagagctga

rs62541922 sense

ccagccgccggcccctcactcgg

rs62541922 antisense

ccgagtgaggggccggcggctgg

rs62541923 sense

ggtccccggccagccctcctcag

rs62541923 antisense

ctgaggagggctggccggggacc

rs200648906 sense

cagctgtcacacacacacgaaaaaaaaattgcggggc

rs200648906 antisense

gccccgcaatttttttttcgtgtgtgtgtgacagctg

86

Site Directed
Mutagenesis
Site Directed
Mutagenesis
Site Directed
Mutagenesis
Site Directed
Mutagenesis
Site Directed
Mutagenesis
Site Directed
Mutagenesis
Site Directed
Mutagenesis
Site Directed
Mutagenesis
Site Directed
Mutagenesis
Site Directed
Mutagenesis
Site Directed
Mutagenesis
Site Directed
Mutagenesis
Site Directed
Mutagenesis
Site Directed
Mutagenesis

Table 5 (Continued)
Primer Name

Sequence

Assay

rs10810657 sense

cttcgttacacagcatatatctgcacccctgcc

rs10810657 antisense

ggcaggggtgcagatatatgctgtgtaacgaag

rs12350739 sense

Gtgctgctgatctcatgcccttcctctgg

rs12350739 antisense

Ccagaggaagggcatgagatcagcagcac

rs77507622 sense

Attccagaaatcattattaggcagtttcttagagcaattcatgggtt

rs77507622 antisense

aacccatgaattgctctaagaaactgcctaataatgatttctggaat

rs10810657_Effect A

ATCACTTCGTTACACAGCATATATCTGCACCCCTGCCGGCA

Site Directed
Mutagenesis
Site Directed
Mutagenesis
Site Directed
Mutagenesis
Site Directed
Mutagenesis
Site Directed
Mutagenesis
Site Directed
Mutagenesis
EMSA

rs10810657_Effect T

TGCCGGCAGGGGTGCAGATATATGCTGTGTAACGAAGTGAT

EMSA

rs10810657_Reference T

ATCACTTCGTTACACAGCATTTATCTGCACCCCTGCCGGCA

EMSA

rs10810657_Reference A

TGCCGGCAGGGGTGCAGATAAATGCTGTGTAACGAAGTGAT

EMSA

rs77507622_Reference A

CCAGAAATCATTATTAGGCAATTTCTTAGAGCAATTCATGG

EMSA

rs77507622_Reference T

CCATGAATTGCTCTAAGAAATTGCCTAATAATGATTTCTGG

EMSA

rs77507622_Effect G

CCAGAAATCATTATTAGGCAGTTTCTTAGAGCAATTCATGG

EMSA

rs77507622_Effect C

CCATGAATTGCTCTAAGAAACTGCCTAATAATGATTTCTGG

EMSA

rs12350739_Effect A

TCATCAGTGCTGCTGATCTCATGCCCTTCCTCTGGCAAACC

EMSA

rs12350739_Effect T

GGTTTGCCAGAGGAAGGGCATGAGATCAGCAGCACTGATGA

EMSA

rs12350739_Reference G

TCATCAGTGCTGCTGATCTCGTGCCCTTCCTCTGGCAAACC

EMSA

rs12350739_Reference C

GGTTTGCCAGAGGAAGGGCACGAGATCAGCAGCACTGATGA

EMSA

rs113780397_Effect A

AGATTGAGCCACTGCACTGCATCCTGGGTGACAGAGCGAGA

EMSA

rs113780397_Effect T

TCTCGCTCTGTCACCCAGGATGCAGTGCAGTGGCTCAATCT

EMSA

rs113780397_Reference G

AGATTGAGCCACTGCACTGCGTCCTGGGTGACAGAGCGAGA

EMSA

rs113780397_Reference C

TCTCGCTCTGTCACCCAGGACGCAGTGCAGTGGCTCAATCT

EMSA

rs117224476_Reference T

TATATTATATATAATGTATATATTATATATTATATAATATA

EMSA

rs117224476_Reference A

TATATTATATAATATATAATATATACATTATATATAATATA

EMSA

rs117224476_Effect G

TATATTATATATAATGTATAGATTATATATTATATAATATA

EMSA

rs117224476_Effect C

TATATTATATAATATATAATCTATACATTATATATAATATA

EMSA

rs12379183_Reference A

GCAAAAAGAACAAAACTGATATTGTTATGTACGGATATTTT

EMSA

rs12379183_Reference T

AAAATATCCGTACATAACAATATCAGTTTTGTTCTTTTTGC

EMSA

rs12379183_Effect G

GCAAAAAGAACAAAACTGATGTTGTTATGTACGGATATTTT

EMSA

rs12379183_Effect C

AAAATATCCGTACATAACAACATCAGTTTTGTTCTTTTTGC

EMSA

rs62541920_Reference G

CATACACAGTGAGTCATTTAGGAGTTTCACATTCTGCCTTC

EMSA

rs62541920_Reference C

GAAGGCAGAATGTGAAACTCCTAAATGACTCACTGTGTATG

EMSA

rs62541920_Effect A

CATACACAGTGAGTCATTTAAGAGTTTCACATTCTGCCTTC

EMSA

rs62541920_Effect T

GAAGGCAGAATGTGAAACTCTTAAATGACTCACTGTGTATG

EMSA

rs10962647_Reference T

CAGCTCTGCTTTTGTCTGCTTCTTTTTGTAATCACATATCT

EMSA

rs10962647_Reference A

AGATATGTGATTACAAAAAGAAGCAGACAAAAGCAGAGCTG

EMSA

rs10962647_Effect G

CAGCTCTGCTTTTGTCTGCTGCTTTTTGTAATCACATATCT

EMSA

rs10962647_Effect C

AGATATGTGATTACAAAAAGCAGCAGACAAAAGCAGAGCTG

EMSA

rs3814113_Major T

CAGGGTACCTGCTCCATATCTTCTGGACCAGTTCTCCAAAC

EMSA
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Table 5 (Continued)
Primer Name

Sequence

Assay

rs3814113_Major A

GTTTGGAGAACTGGTCCAGAAGATATGGAGCAGGTACCCTG

EMSA

rs3814113_minor C

CAGGGTACCTGCTCCATATCCTCTGGACCAGTTCTCCAAAC

EMSA

rs3814113_minor G

GTTTGGAGAACTGGTCCAGAGGATATGGAGCAGGTACCCTG

EMSA

rs181552334_Major A

ATATATATAATATATATTACATAATATATAATATATATAAT

EMSA

rs181552334_Major T

ATTATATATATTATATATTATGTAATATATATTATATATAT

EMSA

rs181552334_minor G

ATATATATAATATATATTACGTAATATATAATATATATAAT

EMSA

rs181552334_minor C

ATTATATATATTATATATTACGTAATATATATTATATATAT

EMSA

BPR1F

CGCTACCACCACCACATACAT

3C

BPAR1F

GCTCTGAACACGCACAGACA

3C

BPR2R

GGTGGTGCACACCTGTAGAG

3C

BPAR2R

GGGCAATGAGCTGTGTCTCT

3C

9p22BNCEcoF1

ACTTTTGGGTAAAGAGGGACAA

3C

9p22BNCpEcoF2

GCTGGCTTGATGCTATTCCC

3C

9p22BNCpEcoF3

AGCAATTTGTGAAGTACCAGGC

3C

9p22BNCEcoR4

GGTATAGTGAGAAGGGCACCA

3C

9p22BNCEcoR5

AACTGAGACCAGACCACAAGT

3C

9p22BNCEcoF6

CACCGCACCGATCCTGTTT

3C

9p22BNCEcoF7

ACTCCAGTCTGGGCAACAAG

3C

9p22BNCEcoF8

GTCATGAGATCGTGGCTGGG

3C

9p22BNCEcoF9

GGCGTGAAACTTCTTGTTATGTGA

3C

9p22BNCEcoF10

GACTGAGCCTGAAGGAAGGC

3C

9p22BNCEcoF11

ACAGATACCAAGTGCAAACTGC

3C

9p22BNCEcoF12

GGGAGGCTGAGACATGAGAC

3C

9p22BNCEcoR13

CCCCATCTGGGACTTGAAGG

3C

9p22BNCEcoR14

CACCAATAAGCGATCAGCTCC

3C

9p22BNCEcoF15

CAGGGCCAAGAATCTACCGC

3C

9p22BNCEcoR16

GAAAAATCACCTGTGTGGGCA

3C

9p22BNCEcoF17

GCACAAGGCCCTTATTCCCA

3C

9p22BNCEcoF18

TGCCTCTGCCAGAATGATGT

3C

9p22BNCEcoR19

TGTGTCATTGAGTGGTGTTGAT

3C

9p22BNCEcoR20

ATCTCTTGAAGCCAGCCATTT

3C

9p22BNCEcoR21

TGTGAGAGTGCCTCGGTGTA

3C

9p22BNCEcoF22

GGCATGCTGCCACATATTCAG

3C

9p22BNCEcoF23

ACCACAGAGAAGGTGGCAAG

3C

9p22BNCEcoR24

TGTTTCCCTCTCCTCCCCAA

3C

9p22CNTLNEcoF1

CATAGGAGATATACATCAGTTGCCA

3C

9p22CNTLNEcoF2

TGGTGCTTGTAGAGGGGTTTC

3C

9p22CNTLNEcoF3

TGGAGACAGGGTAGCGATCA

3C

9p22CNTLNEcoF4

GCTTAGCACTGGACTCAGCA

3C

9p22CNTLNEcoF5

ACCCAACAAGGCTTGAAACA

3C
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Table 5 (Continued)
Primer Name

Sequence

Assay

9p22CNTLNEcoF6

GGGTTGCTAGAGACTTGGGG

3C

9p22CNTLNEcoF7

ATCTCCTCAGTGGCCTTTGT

3C

9p22CNTLNEcoR8

GCCGAGCCCTCATGATGTAA

3C

1-236 FWD

TAGGATCCAGATGGCACACCTTGGGCCCAC

GAL4-BNC2 Constructs

1-524 FWD

TAGGATCCAGATGGCACACCTTGGGCCCAC

GAL4-BNC2 Constructs

1-524 REV

CTGTCGACACTTGCTATGACAGGGGTGG

GAL4-BNC2 Constructs

385-524 FWD

CAGGATCCGAAATGCCCTGACCAGCATTAC

GAL4-BNC2 Constructs

385-524 REV

CTGTCGACACTTGCTATGACAGGGGTGG

GAL4-BNC2 Constructs

519-818 FWD

CAGGATCCCCACCCCTGTCATAGCAAGT

GAL4-BNC2 Constructs

519-818 REV

CTGTCGACTTTGAGGGCTGCCATAATTC

GAL4-BNC2 Constructs

818-1099 FWD

GAGGATCCTGAATTATGGCAGCCCTCAAA

GAL4-BNC2 Constructs

818-1099 REV

AAGTCGACCTAATCTACTGAAGTGAAGG

GAL4-BNC2 Constructs

951-1099 FWD

GAGGATCCGGAGAGGCATGGCAGAGGACTA

GAL4-BNC2 Constructs

951-1099 REV

AAGTCGACCTAATCTACTGAAGTGAAGG

GAL4-BNC2 Constructs

1-1099 FWD

TAGGATCCAGATGGCACACCTTGGGCCCAC

GAL4-BNC2 Constructs

1-1099 REV

AAGTCGACCTAATCTACTGAAGTGAAGG

GAL4-BNC2 Constructs

BNC2 ZF 1,2 FWD

attb-CAGAATTCTGCCCCAGTCAGTG

ZF Protein Constructs

BNC2 ZF 1,2 REV

attb-TACTAGCTGGCTAGGGAGAGGA

ZF Protein Constructs

BNC2 ZF 3,4 FWD

attb-GACATGTTTTACATGAGCCAGT

ZF Protein Constructs

BNC2 ZF 3,4 REV

attb-GTTCAGGTGGGAGTCTTCAGTC

ZF Protein Constructs

BNC2 ZF 5,6 FWD

attb-AGAGGCATGGCAGAGGACTA

ZF Protein Constructs

BNC2 ZF 5,6 REV

attb-ATCTACTGAAGTGAAGGGAA

ZF Protein Constructs

-2184 FWD

CCTGCAGATGCAACCTGTCCCC

Site Specific ChIP

-2184 REV

TCTGCATTCGTGGATTCTGTGCAT

Site Specific ChIP

-914 FWD

GCACAAAACGCTCCGCCACC

Site Specific ChIP

-914 REV

GGCGGAGGAAAACCCAGCGG

Site Specific ChIP

-582 FWD

TTCCTCGGCGTTTCGCAGCC

Site Specific ChIP

-582 REV

GCGGGCGTGGAGGTAGAGGT

Site Specific ChIP
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CHAPTER FIVE:
DISCUSSION

Note to Reader
A manuscript that has been submitted for review includes portions of this
chapter.

Here, we start from EOC GWAS findings and delineate a potential mechanistic
basis for susceptibility at the 9p22.2 locus (Figure 19). We identify allele specific effects
for 5 candidate functional SNPs in three genomic regions, 7, 8 and 11, which contribute
to the regulation of BNC2, a pleiotropic gene encoding a TF involved in ovarian
development, skin pigmentation, and height in fish, mice, and humans.
In Chapter two we identified 5 functional SNPs with allele specific function by
assessing their regulatory potential in several different assays. These assays included
FAIRE-seq and ChIP-seq for histone markers to identify regulatory regions in the locus
as well as luciferase reporter assays measuring said region’s transcription activity.
Allele specific functions were measured with luciferase reporter assays comparing
transcription activity between plasmids with the major and minor allele. EMSA discern
which SNPs have allele specific nuclear extract binding. These assays measure
different yet important mechanisms of transcription therefore we have confidence that
these 5 positive SNPs truly represent the causal SNPs in the 9p22.2 locus.
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Functional analysis of disease susceptibility loci has mainly focused on
associated SNPs that locate to enhancers due to the prevalence of enhancers in the
genome. Yet, evidence for a functional role as an enhancer for Region 11 is weak; it is
not conserved, is highly repetitive, and has few enhancer activity-associated chromatin
features (Figure 10, Figure 8A). Consistent with the data, it displayed significant
luciferase activity in only one experiment (Figure 8B). It failed to show significant 3C
interactions to BNC2 or CNTLN promoters in chapter three (Figure 12C). Moreover,
inspection of histone modifications by ChIP-seq from ENCODE for over 70 cell lines
failed to reveal any chromatin markers associated with enhancers. Thus, it is unlikely
that this region acts as an enhancer even in a different cell type.
In silico analysis suggests that the region may harbor a scaffold/matrix
attachment region (S/MAR). S/MARs have been proposed to assist in chromatin
looping, maintain the local 3D structure of the genome and modulate gene expression
(Linnemann et al., 2009). Importantly, polymorphisms in S/MARs can affect their ability
to attach to the nuclear scaffold/matrix (Kisseljova et al., 2014). It is possible that
S/MARs, which are not well characterized, may play a significant role in the association
with ovarian cancer risk. Quantitative PCR for region 11 in DNA purified from a nuclear
scaffold extract could confirm whether region 11 is indeed a S/MAR. Knocking out
region 11 and looking at changes in expression of potential downstream targets would
identify the target gene of region 11. As mentioned earlier, S/MARs are not well
characterized therefore changes in DNA binding to the nuclear scaffold may have an
entirely unique effect on development and cancer oncogenesis outside of the realm of
transcription regulation.
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In Chapter Three, we identified BNC2 as the major target of the 9p22 causal
SNPs. In ovarian cells, the promoter of BNC2 is active and transcripts for BNC2 are
present. Additionally two of the causal SNPs in Region 7 implicate BNC2 as a target
gene as they are located in its major promoter. Two of the causal SNPs in Region 8
overlap with enhancer marks and physically interact with the BNC2 promoter. Thus,
these regions, conserved in mouse, contribute to the regulation of BNC2 expression
(Figure 10).
Our data indicate that the mechanism by which genetic variation at the locus
affect ovarian cancer susceptibility may be mediated primarily by multiple non-coding
elements including enhancer and promoter elements which target BNC2 and by a
putative S/MAR element. Limitations of this work include the possibility that enhancer
landscapes may change significantly during development (Pennacchio et al., 2006), the
limited regulatory profiling information that has been performed in ovarian cells (e.g.
lack of CTCF repressor marks and putative non-coding RNA elements data) and the
possibility of false positive and false negative findings.
However, several lines of evidence suggest that we have captured the functional
features relevant to ovarian cancer risk. First, our use of a large panel of ovarian normal
and cancer cell lines derived from different origins provide a broad view of regulatory
activity. Second, most (~90%) enhancers are linked to single promoter in primary
mouse cells (Kieffer-Kwon et al., 2013) supporting the hypothesis that Region 8 targets
BNC2 exclusively although it is unclear how other regulatory features present in the
locus might interact with the regulatory network described here. For example, large
active enhancer clusters that drive expression of cell identity genes, also called super
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enhancers (Hnisz et al., 2013) are nearby. This paper discusses that the repertoire of
cell identity genes mostly includes TFs which in turn use an auto-regulatory loop to
regulate their own expression by binding to these super enhancers. This super
enhancer (Figure 19B) contains BNC2 binding sites defined by our ChIP-seq data
suggesting that BNC2 represents a cell identity gene or master regulator in ovarian
cells.
In Chapter Four we show that BNC2, an ancient gene with potentially very
important functions in living organisms, acts as a transcription regulator in enhancer
regions potentially through recruitment of the NuRD complex of chromatin remodeling
(Gunther et al., 2013; Hu and Wade, 2012; Ramirez and Hagman, 2009). We also show
that BNC2 targets enhancer regions likely operating to modulate the expression of
downstream genes involved in cell-cell and cell-extracellular matrix communication.
Genome-wide and candidate gene association studies have identified significant
associations between the 9p22.2 locus and skin pigmentation in Europeans
(rs10756819) (Jacobs et al., 2013) and Asians (Hider et al., 2013), and freckling
(rs2153271) (Eriksson et al., 2010) (Figure 19B). Importantly, functional dissection
identified rs12350739 as the likely causal variant associated with saturation of skin color
(Visser et al., 2014). This SNP is one of the functional SNPs identified in the present
study mapping to a BNC2 enhancer (Region 8). The locus also contains a region of
Neanderthal DNA (Chr9: 16,720,121-16,786,930) thought to confer adaptive advantage
to colder climates by modulation of skin pigmentation (Sankararaman et al., 2014;
Vernot and Akey, 2014) (Figure 19B). In addition, the locus has been found to be
associated with human height (rs2149163 and rs3927536) (Wood et al., 2014) (Figure
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19B). In relation to EOC, the locus is associated to abnormal ovarian ultrasound results
(rs12379183, a functional SNP in the present study located in Region 7) (Figure 19B).
The link between BNC2 and ovarian biology is further supported by the results of
deletion of BNC2 in mice and zebrafish. In the bonaparte mutants, in addition to the
defect in skin pigmentation (lack of body stripes) and stunted growth, the ovaries are
dysmorphic leading to infertility (Lang et al., 2009). In mice, Bnc2 is expressed in
ovarian somatic cells such as theca cells and Bnc2-/- female mice present with an
excess of stromal cells and a greatly reduced number of oocytes leading to infertility
(Philippe Djian, personal communication). These mice are also born abnormally small
with cleft palates suggesting that bnc2 plays a role in skeletal development
(Vanhoutteghem et al., 2009). This data suggests that the bnc2 mutants/knock-outs in
model organisms influence the same traits identified to be associated with the locus
further supporting that BNC2 is the target gene.
Decreased parity is a major risk factor for ovarian cancer and disruption of BNC2
in zebrafish and mice indicate its role in fertility. Additionally, evidence suggesting that
BNC2 is an ovarian cell identity gene/master regulator indicates its role in ovarian
development and maintenance of function. Therefore BNC2 may indirectly influence
ovarian cancer risk by primarily influencing ovarian development and fertility. Additional
functional assays studying ovarian development and the menstrual cycle, such as
conditional knock-outs of BNC2, may inform the role of BNC2 in ovarian development
and fertility.
In summary, we propose that the mechanism of ovarian cancer susceptibility in
the 9p22.2 locus is likely mediated by changes in a transcriptional regulatory network
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involving several enhancer and promoter elements acting on BNC2 and a putative
S/MAR region. While our data strongly suggests that the association signal is mediated
through BNC2 regulation the individual contribution of each element and gene(s) to risk
must wait further analysis.

Figure 19: Outline of the study. A. Summary of identifying the functional SNPs. B.
Further evidence tells us that the 9p22 locus and BNC2 are important. An introgressed
Neanderthal region (light blue bar) lies within the BNC2 gene and may influence
pigmentation. Two super enhancers (red bars) lie on and near the BNC2 gene and are
believed to mainly target TFs involved in cell type identity. Other SNPs at the locus are
implicated in abnormal ovarian ultrasound as well as skin color and pigmentation
(green).
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